
==== Front
Transl Neurodegener
Transl Neurodegener
Translational Neurodegeneration
2047-9158
BioMed Central London

435
10.1186/s40035-024-00435-8
Review
Neurodegenerative disorders, metabolic icebergs, and mitohormesis
http://orcid.org/0000-0003-4183-7766
Phillips Matthew C. L. Matthew.Phillips@waikatodhb.health.nz

12
http://orcid.org/0000-0003-2835-0478
Picard Martin 3456
1 https://ror.org/002zf4a56 grid.413952.8 0000 0004 0408 3667 Department of Neurology, Waikato Hospital, Hamilton, 3204 New Zealand
2 https://ror.org/03b94tp07 grid.9654.e 0000 0004 0372 3343 Department of Medicine, University of Auckland, Auckland, 1142 New Zealand
3 https://ror.org/01esghr10 grid.239585.0 0000 0001 2285 2675 Division of Behavioral Medicine, Department of Psychiatry, Columbia University Irving Medical Center, New York, NY 10032 USA
4 https://ror.org/01esghr10 grid.239585.0 0000 0001 2285 2675 Department of Neurology, H. Houston Merritt Center, Columbia Translational Neuroscience Initiative, Columbia University Irving Medical Center, New York, NY 10032 USA
5 https://ror.org/04aqjf708 0000 0001 0690 8560 New York State Psychiatric Institute, New York, NY 10032 USA
6 https://ror.org/00hj8s172 grid.21729.3f 0000 0004 1936 8729 Robert N Butler Columbia Aging Center, Columbia University Mailman School of Public Health, New York, NY USA
6 9 2024
6 9 2024
2024
13 4622 4 2024
25 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Neurodegenerative disorders are typically “split” based on their hallmark clinical, anatomical, and pathological features, but they can also be “lumped” by a shared feature of impaired mitochondrial biology. This leads us to present a scientific framework that conceptualizes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD) as “metabolic icebergs” comprised of a tip, a bulk, and a base. The visible tip conveys the hallmark neurological symptoms, neurodegenerative regions, and neuronal protein aggregates for each disorder. The hidden bulk depicts impaired mitochondrial biology throughout the body, which is multifaceted and may be subdivided into impaired cellular metabolism, cell-specific mitotypes, and mitochondrial behaviours, functions, activities, and features. The underlying base encompasses environmental factors, especially modern industrial toxins, dietary lifestyles, and cognitive, physical, and psychosocial behaviours, but also accommodates genetic factors specific to familial forms of AD, PD, and ALS, as well as HD. Over years or decades, chronic exposure to a particular suite of environmental and genetic factors at the base elicits a trajectory of impaired mitochondrial biology that maximally impacts particular subsets of mitotypes in the bulk, which eventually surfaces as the hallmark features of a particular neurodegenerative disorder at the tip. We propose that impaired mitochondrial biology can be repaired and recalibrated by activating “mitohormesis”, which is optimally achieved using strategies that facilitate a balanced oscillation between mitochondrial stressor and recovery phases. Sustainably harnessing mitohormesis may constitute a potent preventative and therapeutic measure for people at risk of, or suffering with, neurodegenerative disorders.

Keywords

Alzheimer’s disease
Parkinson’s disease
Amyotrophic lateral sclerosis
Huntington’s disease
Splitting
Lumping
Mitochondria
Mitotypes
Hormesis
Mitohormesis
issue-copyright-statement© Ruijin Hospital, Shanghai Jiao Tong University 2024
==== Body
pmcBackground

The cause is secret, but th’ effect is known.

- Ovid [1].

Despite decades of investment and research, neurodegenerative disorders are becoming increasingly common. As of 2017, the global prevalence of Alzheimer’s disease (AD) and other dementias stood at 45 million people [2]. Another 8.5 million people were living with Parkinson’s disease (PD) [2]. Both AD and PD are doubling in prevalence every 20–30 years [3, 4]. Amyotrophic lateral sclerosis (ALS) afflicts 4.1–8.4 of every 100,000 people, or roughly 500,000 people globally [5]. The prevalence of ALS is increasing by approximately 70% every 25 years [6]. Lastly, Huntington’s disease (HD) afflicts 4.9 of every 100,000 people, or roughly 400,000 people globally [7]. The prevalence of HD increased by approximately 80% in the last 35 years. Although much of the rise in prevalence is explained by earlier diagnoses, population aging, and population growth, there may be a significant contribution from modifiable environmental factors [8, 9]. Unless we stem this rising tide, the ensuing socio-economic impact is poised to exceed the management capacity of many healthcare systems.

Splitting and lumping

Rather than investing further resources into lines of research that have (so far) failed to stem the tide, it is worth considering how our chosen methods of classifying neurodegenerative disorders influence how we approach and treat them. In 1857, Darwin distinguished between two kinds of individuals, whom he called “splitters” and “lumpers” [10]. Splitters are people who make classifications based on distinct characteristics, which leads to multiple classification schemes that reflect these distinctions. Lumpers, by contrast, make classifications in a broad manner, which allows for ranges of characteristics to be classified into fewer entities. Ideally, a compromise between splitting and lumping might constitute the best approach to conceptualizing many of the medical disorders encountered in healthcare. However, due to a lengthy history of medical reductionism, the balance is currently heavily tilted towards splitting, which leads to difficulties when it comes to “putting the patient back together” [11].

Neurodegenerative disorders are typically split based on their hallmark clinical, anatomical, and pathological features (Fig. 1) [12]. Splitting enables clinical diagnosis and management by identifying common clinico-pathological patterns, conveying prognostic information, and facilitating symptom-based treatments. However, it leads to several problems. First, splitting does not sufficiently emphasize the broader array of neurological symptoms in these disorders, particularly the non-cognitive symptoms of AD [13, 14], the non-motor symptoms of PD [15, 16], and the cognitive and behavioural symptoms of ALS and HD [17, 18]. Many of these symptoms arise from neurodegenerative changes outside the hallmark regions [14, 16, 19, 20]. Second, splitting does not explain why degenerative changes frequently occur in non-neurological tissues, particularly the skeletal muscles and heart [21–24]. We lack an understanding as to how these disorders manifest outside the nervous system. Third, splitting biases treatment efforts towards targeting and suppressing the hallmark symptoms and aggregates [25, 26]. However, these allopathic approaches have not produced clinically meaningful outcomes, and may lead to harm [27]. Essentially, splitting portrays neurodegenerative disorders as focal neurological disorders amenable to targeted, suppressive treatments, but fails to address their etiology and multisystemic nature.Fig. 1 Splitting perspective of neurodegenerative disorders. AD Alzheimer’s disease, VD vascular dementia, DLB dementia with Lewy bodies, FTD frontotemporal dementia, PD Parkinson’s disease, MSA multiple systems atrophy, PSP progressive supranuclear palsy, CBD corticobasal degeneration, ALS amyotrophic lateral sclerosis, PLS primary lateral sclerosis, PMA progressive muscular atrophy, HD Huntington’s disease, TDP-43 transactive response DNA binding protein 43, HTT Huntingtin

Alternatively, this splitting paradigm can be integrated with a lumping perspective that emphasizes a shared feature of impaired mitochondrial biology, which has been documented across a wide range of neurodegenerative disorders, including AD, PD, ALS, and HD (Fig. 2) [28–30]. Although traditionally described as cell “powerhouses”, mitochondria are more comprehensively described as cell “processors” that coordinate energy and metabolism throughout the body [31, 32]. Distributed mitochondrial networks sense and communicate bioenergetic states to ensure that cellular behaviours match energy availability and demands [32]. Mitochondria also coordinate an array of processes, including epigenetic modifications, adenosine triphosphate (ATP) production, reactive oxygen species (ROS) emission, hormone biosynthesis, and neurotransmitter metabolism [31–34]. Moreover, in the same way that organisms are composed of highly specialized organs and cell types that perform complementary functions, recent evidence has revealed a diverse family of cell-specific mitochondrial phenotypes or “mitotypes” throughout the brain, each of which is energetically and metabolically optimized to meet the requirements of a particular subset of neurons and brain regions [35–38]. Based on this emerging understanding of mitochondria, a lumping perspective recognizes the hallmark clinical, anatomical, and pathological features of each neurodegenerative disorder as offshoots of a common bioenergetic and metabolic etiology, which maximally impacts subsets of mitotypes abundant in the afflicted brain regions. Lumping explains the diversity of symptoms and degenerative changes documented in other areas of the nervous system, the skeletal muscles, and heart, as all these tissues are rich in mitochondria. It also implies that approaches geared towards allopathic targeting and suppression are of limited benefit in the setting of impaired mitochondrial biology, which fundamentally requires a restorative approach [9, 39]. Essentially, lumping neurodegenerative disorders by their impaired mitochondrial biology enables them to be conceptualized as multisystemic disorders in need of multisystemic, restorative therapies.Fig. 2 Lumping perspective of neurodegenerative disorders. AD Alzheimer’s disease, PD Parkinson’s disease, ALS amyotrophic lateral sclerosis, HD Huntington’s disease

Perspective

We will discuss how the current splitting paradigm can be integrated with a lumping perspective, which converges upon impaired mitochondrial biology as the etiology and core disease in the most common neurodegenerative disorders. This integration will expand upon previous similar proposals by providing a scientific framework that portrays how this common (lumped) disease process drives the hallmark (split) features of each disorder. This framework will then be utilized to identify and discuss preventative and therapeutic strategies that show promise in repairing and recalibrating mitochondrial biology. Supportive evidence will be mostly derived from human studies, emphasizing interventional studies where possible.

Neurodegenerative disorders as metabolic icebergs

Each neurodegenerative disorder may be conceptualized as a “metabolic iceberg” comprised of a tip, a bulk, and a base (Fig. 3). The hallmark clinical, anatomical, and pathological features are illustrated in the tip, which emerge as downstream effects of the core disease, impaired mitochondrial biology, in the bulk, which in turn is triggered by a particular suite of environmental and genetic factors in the base. This section will outline a comprehensive scientific framework for conceptualizing the pathogenesis of any neurodegenerative disorder. Subsequent sections will apply this framework to the common neurodegenerative disorders that plague modern healthcare, specifically AD, PD, ALS, and HD.Fig. 3 The metabolic iceberg view of neurodegenerative disorders. This framework conveys the pathogenesis of each neurodegenerative disorder, which commences at the base, proceeds through the bulk, and eventually surfaces at the tip

Tip of the iceberg

The tip of the metabolic iceberg conveys the clinical, anatomical, and pathological features for each neurodegenerative disorder, the most visible of which are the “hallmark” features. The highest and most visible level, the level of the organism, encapsulates the hallmark neurological symptoms for each disorder, which are diagnosed and managed by clinicians. The middle level, the level of body systems, organs, and tissues, describes the hallmark neurodegenerative regions, which may be identified on neuroimaging and occasionally addressed with surgical techniques [40, 41]. The lowest level, the level of the cell, comprises the hallmark neuronal protein aggregates, which may be identified by circulating biomarkers and are typically addressed with targeted, suppressive approaches [25, 26].

Bulk of the iceberg

The bulk of the metabolic iceberg represents impaired mitochondrial biology throughout the body, which lies below the clinical waterline and remains relatively unexplored. Impaired mitochondrial biology may be subdivided into several levels, with several facets attributed to each [31]. The highest and most complex level encapsulates impaired cellular metabolism, which maximally impacts neurons in the hallmark neurodegenerative regions [42–45], but also affects other metabolically active non-neuronal cells throughout the brain and body, such as glia and myocytes [46–48]. The second level describes impaired cell-specific mitotypes (characteristics of mitochondria relevant to a specific cell type), such as an altered mitochondrial content and distribution within neurons. The third level comprises impaired mitochondrial behaviours (goal-directed processes involving the whole mitochondrion), which include disruptions in mitochondrial fusion and fission, motility, biogenesis (mitogenesis), and autophagy (mitophagy). The fourth level describes impaired mitochondrial functions (integrated processes involving multiple mitochondrial components), such as decreased ATP synthesis, increased ROS emission, dysregulated calcium regulation, and altered steroidogenesis. The fifth level comprises impaired mitochondrial activities (processes involving individual mitochondrial components), which include reduced enzymatic activities in the tricarboxylic acid (TCA) cycle and electron transport chain (ETC). The lowest level denotes impaired mitochondrial features (static molecular components), such as altered mitochondrial shape and size, as well as damage to cristae and mitochondrial DNA (mtDNA).

Base of the iceberg

The base of the metabolic iceberg is represented by environmental and genetic factors that damage mitochondria or force maladaptive adjustments in their biology. Observational evidence in humans implicates environmental factors related to modern lifestyles as the key drivers of impaired mitochondrial biology, particularly in sporadic AD, PD, and ALS [8, 9]. First, substantial evidence implicates modern industrial toxins, such as heavy metals, air pollutants, pesticides, and chemicals, as major contributory factors to the neurodegenerative process [8]. These toxins accumulate in mitochondria and induce oxidative damage [49]. Second, growing evidence implicates the modern dietary lifestyle, which is characterized by a high intake of processed, carbohydrate-rich foods combined with multiple daily meals and snacks [9]. This dietary lifestyle is evolutionarily unprecedented and leads to a combination of chronic energy overload and insufficient recovery time that drives oxidative damage in mitochondria [50]. Third, modern cognitive, physical, and psychosocial behaviours lead to deficiencies in authentic cognitive, physical, and psychosocial interactions, as well as disrupted sleep and rest states. These behavioural factors get “under the skin” through an array of psychobiological pathways that energetically converge upon mitochondria [51]. Interventional evidence derived from human, animal, and cell models also demonstrates that an array of genetic factors can drive impaired mitochondrial biology and trigger familial forms of AD, PD, and ALS, as well as HD [52–55]. Most of these are gene mutations, which express toxic protein products that directly damage mitochondria. However, a loss of normal protein function can also compromise mitochondria by forcing maladaptive adjustments in their biology.

Iceberg pathogenesis

The metabolic iceberg framework conveys a comprehensive overview of the pathogenesis of each neurodegenerative disorder. This process commences at the base, proceeds through the bulk, and eventually surfaces at the tip. Based on this framework, a detailed understanding of the tip enables clinical diagnosis and management, but it provides limited tractable information to guide prevention or therapy. Conversely, an understanding of the bulk and the base sheds light on strategies that may act in the interest of prevention and therapy by inducing “salugenesis” [39].

Neurodegenerative disorders commence at the base. Chronic exposure to a particular “suite” of environmental and genetic factors damages mitochondria or forces maladaptive adjustments, which elicits a particular trajectory of impaired mitochondrial biology that eventually surfaces with the hallmark features of AD, PD, ALS, or HD. Under the metabolic iceberg framework, sporadic AD, PD, and ALS are primarily driven by environmental factors. Many of these factors are broadly implicated in the etiology of multiple disorders, such as lead exposure in AD, PD, and ALS [56–58]. Others are more specifically linked to the etiology of a particular disorder, such as air particulate matter exposure in AD [56], rotenone exposure in PD [57], and electrical exposure in ALS [58]. Familial forms of AD, PD, and ALS, and all cases of HD, are primarily driven by genetic factors that impair mitochondrial biology. Most of these are gene mutations, which act as highly specific triggers of a particular disorder [52–55].

Neurodegenerative disorders proceed through the bulk for years or decades. During this time, the suite of instigating factors induces multifaceted, multisystemic impairments in mitochondrial biology that maximally impact subsets of mitotypes abundant in the eventual hallmark neurodegenerative regions particular to AD, PD, ALS, or HD. Mitochondria in these regions begin to exhibit impaired biology on multiple levels, including decreased ATP production and increased ROS emission leading to oxidative damage [59], which may represent the earliest event in pathogenesis [60]. Given that mitochondria constitute the main intracellular source of ROS [61], mitochondrial oxidative damage elicits an upsurge in ROS emission, which may be followed by a vicious cycle of ROS-induced ROS release that drives further oxidative damage [62]. The ROS overflow also triggers neuroinflammation and lysosome dysfunction, both of which can, in turn, induce further mitochondrial damage [63–65]. Depending on the particular suite of initiating environmental and genetic factors, the trajectory of impaired mitochondrial biology maximally impacts subsets of mitotypes abundant in the hallmark neurodegenerative regions particular to AD, PD, ALS, or HD, which leads to a relatively pronounced failure of energy and metabolism in these regions. This is consistent with findings from positron emission tomography (PET) studies showing that deficits in mitochondrial energy metabolism occur early in the hallmark regions, often years before the clinical symptoms [42–45].

The hallmark features of AD, PD, ALS, or HD surface at the tip. These features represent a late-stage effect that follows years or decades of impaired mitochondrial biology in the hallmark neurodegenerative regions. Perhaps controversially, the metabolic iceberg largely positions the hallmark neuronal protein aggregates as downstream consequences of impaired mitochondrial biology. This conceptualization is supported by studies demonstrating that mitochondria-mediated oxidative stress both precedes and promotes the deposition of the aggregates [66–71]. However, the iceberg framework can also accommodate evidence that the aggregates can, in turn, damage mitochondria in a reciprocal manner [72]. Beyond the hallmark regions, mitochondria in other areas of the nervous system are impaired, which leads to the broader array of neurological symptoms observed in these disorders, including the non-cognitive symptoms of AD [13, 14], the non-motor symptoms of PD [15, 16], and the cognitive and behavioural symptoms of ALS and HD [17, 18]. Impaired mitochondrial biology outside the nervous system also leads to degenerative changes in the skeletal muscles, heart, and other metabolically active tissues, followed by more generalized symptoms such as muscle wasting and weight loss [73].

AD as a metabolic iceberg

AD may be conceptualized as a metabolic iceberg, with the hallmark clinical, anatomical, and pathological features emerging as late-stage effects of impaired mitochondrial biology (Fig. 4). We propose that chronic exposure to a particular suite of environmental and genetic factors elicits a trajectory of impaired mitochondrial biology that maximally impacts subsets of mitotypes abundant in the hippocampus, entorhinal cortex, and cerebral cortex, which eventually surfaces as the hallmark features of AD.Fig. 4 AD as a metabolic iceberg. AD Alzheimer’s disease, ATP adenosine triphosphate, TCA tricarboxylic acid, ETC electron transport chain, mtDNA mitochondrial DNA, APOE4 apolipoprotein E4

AD: base of the iceberg

Human observational studies implicate environmental factors related to modern lifestyles as primary drivers of impaired mitochondrial biology in AD [8, 9]. Modern industrial toxins include heavy metals (such as aluminum, lead, copper, and arsenic), air pollutants (such as particulate matter and ozone), pesticides (such as organochlorines and organophosphates), flame retardants, and plasticizers [56]. The modern dietary lifestyle is the primary driver for the rising rates of mid-life obesity, type 2 diabetes, and hypertension, each of which increases the risk of developing AD [74]. Alcohol is an established risk factor [75]. Fewer years of formal education, physical inactivity, depression, chronic social isolation, and sleep disturbances are also associated with an increased risk of developing AD [74, 75]. Beyond these environmental factors, a number of genetic factors link impaired mitochondrial biology to the pathogenesis of AD [52]. Apolipoprotein E4 (APOE4), a major genetic risk factor for AD, targets and disrupts mitochondrial ATP production and ROS emission [76]. The mutant amyloid precursor protein accumulates in the protein import channels of mitochondria, where it inhibits complex IV activity and increases ROS emission [77]. Mutant presenilins 1 and 2 disrupt mitochondrial calcium signalling, which leads to decreased ATP production, increased ROS emission, and cell death [78].

AD: bulk of the iceberg

Human neuroimaging and post-mortem studies show that impaired mitochondrial biology occurs early in the pathogenesis of AD [79]. PET studies have detected glucose hypometabolism in the hippocampus, entorhinal cortex, and cerebral cortex, which may occur 30–40 years prior to the clinical symptoms [42]. Cerebral hypometabolism develops in concert with impaired brain insulin signalling, which has led to AD being described as “type 3 diabetes” [80]. Phenotypically, cortical neuron mitochondria show reduced numbers, particularly within synapses [81, 82]. They also display a disturbed balance between fusion and fission, disrupted motility, and defective mitophagy [83–85]. Functionally, cortical neuron mitochondria exhibit decreased ATP synthesis and oxidative damage, which not only precede the clinical symptoms [86], but can also precede and promote the deposition of amyloid-β and tau [66, 67]. They also show evidence of calcium dysregulation [87]. Moreover, cortical neuron mitochondria demonstrate inhibited enzyme activities in the TCA cycle and ETC (particularly complex IV) [88]. Lastly, hippocampal and cortical neuron mitochondria display increased variability in shape, decreased size, altered cristae, and oxidative damage to mtDNA [89].

AD: tip of the iceberg

After years or decades of impaired mitochondrial biology, the tip emerges as AD, which is typically diagnosed in the setting of progressive cognitive impairment culminating in dementia [90]. This clinical progression may be accompanied by neurodegenerative changes in the hippocampus, entorhinal cortex, and cerebral cortex, as well as biomarker evidence of amyloid-β and tau [91]. However, numerous non-cognitive symptoms may accompany the hallmark cognitive symptoms, which include loss of smell, pain syndromes, gait dysfunction, agitation, aggression, circadian rhythm disruptions, sleep disturbances, and weight loss [13, 14]. Accordingly, neurodegenerative changes are present in other areas of the nervous system, such as the olfactory bulb and cervical spine [13, 14], and amyloid-β and tau aggregates may be detected in virtually all tissues outside the nervous system, including the skeletal muscles, heart, adrenal glands, kidneys, liver, pancreas, stomach, bowel, spleen, lymph nodes, thyroid, aorta, lung, testes, and ovaries [21].

PD as a metabolic iceberg

PD may also be conceptualized as a metabolic iceberg, with the hallmark clinical, anatomical, and pathological features emerging as late-stage effects of impaired mitochondrial biology (Fig. 5). We propose that chronic exposure to a particular suite of environmental and genetic factors elicits a trajectory of impaired mitochondrial biology that maximally impacts subsets of mitotypes abundant in the substantia nigra, striatum, and cerebral cortex, which eventually surfaces as the hallmark features of PD.Fig. 5 PD as a metabolic iceberg. PD Parkinson’s disease, ATP adenosine triphosphate, ETC electron transport chain, mtDNA mitochondrial DNA, PRKN Parkin, PINK1 phosphate and tensin homolog-induced kinase 1

PD: base of the iceberg

Human observational studies implicate environmental factors related to modern lifestyles as primary drivers of impaired mitochondrial biology in PD [8, 9]. Modern industrial toxins include heavy metals (such as iron, lead, manganese, and mercury), pesticides (such as organophosphates, rotenone, and paraquat), and solvents [57]. Notably, rotenone is a mitochondrial complex I inhibitor that induces parkinsonism in animal models [92]. Another mitochondrial toxin and complex I inhibitor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, triggers parkinsonism in humans [93]. The modern dietary lifestyle is associated with an increased risk of PD progression—foods typically low in carbohydrates (or, when carbohydrates are present, they are high in fiber) are associated with reduced progression, whereas foods associated with more rapid progression are typically high in processed carbohydrates [94]. Lower coffee consumption is an established risk factor [95]. Physical inactivity and social withdrawal are also associated with an increased risk of PD development and progression [95, 96]. Beyond these environmental factors, a number of genetic factors link impaired mitochondrial biology to the pathogenesis of PD [53]. Mutations in parkin (PRKN) or phosphate and tensin homolog-induced kinase 1 (PINK1) prevent cells from responding to mitochondrial damage by altering the balance of fusion to fission and disrupting mitophagy, which leads to familial forms of PD [97, 98].

PD: bulk of the iceberg

Human neuroimaging and post-mortem studies show that impaired mitochondrial biology occurs early in the pathogenesis of PD [99]. PET studies have detected glucose hypometabolism in the substantia nigra, striatum, and cerebral cortex [43]. Phenotypically, platelet mitochondria exhibit an altered distribution, preferentially accumulating around the nucleus [100]. Neurons also show decreased levels of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), a key regulator of mitogenesis [101], and mitochondria display disturbances in fusion and fission, motility, and mitophagy in familial forms of PD [53]. Functionally, synaptic mitochondria are extrapolated to have a 35%–40% decrease in ATP synthesis based on the reported decrease in complex I activity [102], as well as elevated markers of oxidative damage [103]. This mitochondria-mediated oxidative stress precedes and promotes the deposition of α-synuclein [68, 69]. Moreover, mitochondria from substantia nigra neurons, skeletal myocytes, and platelets show inhibited enzyme activities in the ETC (particularly complex I) [104–106]. Lastly, platelet-derived mitochondria from PD cybrid cells exhibit abnormal features, which include an enlarged or swollen shape, pale matrix, and few remaining cristae [107], and substantia nigra neuron mitochondria in older people with parkinsonism display abundant deletions in mtDNA [108].

PD: tip of the iceberg

After years or decades of impaired mitochondrial biology, the tip emerges as PD, which is typically diagnosed in the setting of motor symptoms consistent with parkinsonism [109]. These symptoms may be accompanied by neurodegenerative changes in the substantia nigra and striatum, as well as biomarker evidence of oligomeric α-synuclein [110]. However, numerous non-motor symptoms may accompany the hallmark motor symptoms, which include loss of smell, pain syndromes, depression, anxiety, urinary and gastrointestinal dysfunction, sleep disorders, cognitive impairment, apathy, and weight loss [15, 16]. Accordingly, neurodegenerative changes are present in other areas of the nervous system, such as the peripheral, autonomic, and enteric nervous systems [15, 16], and α-synuclein aggregates may be detected outside the nervous system, including in the digestive tract, skeletal muscles, heart, adrenal glands, kidneys, urogenital system, and skin [22].

ALS as a metabolic iceberg

ALS may also be conceptualized as a metabolic iceberg, with the hallmark clinical, anatomical, and pathological features emerging as late-stage effects of impaired mitochondrial biology (Fig. 6). We propose that chronic exposure to a particular suite of environmental and genetic factors elicits a trajectory of impaired mitochondrial biology that maximally impacts subsets of mitotypes abundant in the brainstem and motor cortex, which eventually surfaces as the hallmark features of ALS.Fig. 6 ALS as a metabolic iceberg. ALS amyotrophic lateral sclerosis, TDP-43 transactive response DNA binding protein 43, ATP adenosine triphosphate, TCA tricarboxylic acid, ETC electron transport chain, mtDNA mitochondrial DNA, C9orf72 chromosome 9 open reading frame 72, SOD1 superoxide dismutase 1, FUS fused in sarcoma

ALS: base of the iceberg

Human observational studies implicate environmental factors related to modern lifestyles as primary drivers of impaired mitochondrial biology in ALS [8, 9]. Modern industrial toxins include heavy metals (such as lead, iron, manganese, and selenium) and pesticides (such as organochlorines, pyrethoids, herbicides, and fumigants) [58]. Electrical occupations involving repeated exposures to electrical shocks or electromagnetic fields are associated with an increased risk of developing ALS [111]. Smoking is an established risk factor [112]. Exercise may be a two-edged sword, as people engaged in organized sport have a 51% lower risk of developing ALS, but professional athletes have a 59% higher risk [113]. Higher cardiovascular fitness, but not muscle strength, is also associated with an increased risk of ALS later in life [114]. Beyond these environmental factors, a number of genetic factors link impaired mitochondrial biology to the pathogenesis of ALS [54]. Mutations in chromosome 9 open reading frame 72 (C9orf72) compromise mitochondrial function and increase oxidative stress in motor neurons [115]. Superoxide dismutase 1 (SOD1) normally breaks down superoxide; mutations in SOD1 can induce oxidative damage in motor neuron mitochondria and trigger the clinical symptoms of ALS [116]. Mutant fused in sarcoma (FUS), which also promotes mitochondrial damage [117], can trigger aggressive familial forms of ALS [118].

ALS: bulk of the iceberg

Human neuroimaging and post-mortem studies show that impaired mitochondrial biology occurs early in the pathogenesis of ALS [54]. PET studies have detected glucose hypometabolism in the frontal, motor, and occipital cortices [44]. Phenotypically, motor neuron mitochondria display an altered distribution, preferentially gathering in the soma [119]. Disturbed mitochondrial transport along motor neuron axons and defective mitophagy are among the earliest pathophysiological events [120]. Functionally, spinal cord neurons, lymphocytes, and skeletal myocytes exhibit decreased ATP synthesis, oxidative damage, and calcium dysregulation [121–123]. Mitochondria-mediated oxidative stress can both precede and promote the deposition of transactive response DNA binding protein 43 (TDP-43) [70, 71]. Mitochondria in spinal cord neurons, lymphocytes, and skeletal myocytes also demonstrate inhibited activities in citrate synthase and ETC complexes I–IV [121, 122, 124, 125]. Moreover, motor neuron mitochondria show abnormal features, including a swollen appearance, markedly increased cristae, and oxidative damage to mtDNA [119, 121]. Altogether, these multifaceted mitochondrial alterations would be expected to lead to a series of energetically costly adjustments, including compensatory hypermetabolism in the spinal cord and skeletal muscles [126, 127]. Despite these adjustments, impaired mitochondrial biology still ripples out at the level of the organism.

ALS: tip of the iceberg

After years or decades of impaired mitochondrial biology, the tip emerges as ALS, which is typically diagnosed in the setting of limb or bulbar weakness supported by characteristic changes on electromyography [128]. These symptoms may be accompanied by neurodegenerative changes in the brainstem and motor cortex, as well as biomarker evidence of TDP-43 [129, 130]. However, many additional symptoms may accompany the hallmark limb or bulbar weakness, which include executive dysfunction, language impairment, disinhibition, loss of empathy, apathy, muscle wasting, and weight loss [17]. Accordingly, neurodegenerative changes are present elsewhere in the nervous system, such as other regions of cerebral cortex, the hippocampus, and cerebellum [19]. Outside the nervous system, TDP-43 aggregates may be detected in the skeletal muscles and heart [23].

HD as a metabolic iceberg

Although HD is commonly described as a monogenic disorder, it can still be conceptualized as a metabolic iceberg, with the hallmark clinical, anatomical, and pathological features emerging as late-stage effects of impaired mitochondrial biology (Fig. 7). We propose that chronic exposure to mutant huntingtin (HTT) elicits a trajectory of impaired mitochondrial biology that maximally impacts subsets of mitotypes abundant in the striatum and cerebral cortex, which eventually surfaces as the hallmark features of HD.Fig. 7 HD as a metabolic iceberg. HD Huntington’s disease, HTT Huntingtin, ATP adenosine triphosphate, ETC electron transport chain, mtDNA mitochondrial DNA

HD: base of the iceberg

The HTT gene codes for the HTT protein, which is ubiquitously expressed throughout the body [131]. This protein is involved in many different processes related to immunity, gene expression, cellular metabolism, and a range of mitochondrial functions and activities [55, 132, 133]. Beyond a certain threshold, a CAG repeat expansion in the HTT gene leads to the expression of the mutant HTT protein, which can facilitate mitochondrial damage on many levels [55]. Moreover, since normal HTT protein is essential for mitochondrial bioenergetics and metabolism [134], a loss of normal function would also be expected to trigger maladaptive adjustments in mitochondrial biology [135]. Despite the pivotal role of mutant HTT in triggering and driving HD, growing evidence indicates that its symptomatic expression is significantly influenced by environmental factors [136, 137], such that even monozygotic twins bearing the same number of CAG repeats may show considerable differences in the age of onset and nature of their HD symptoms [138, 139]. Malonate, a mitochondrial toxin and complex II inhibitor, can trigger striatal lesions in animal models that closely resemble those of HD [140]. Dietary lifestyle may influence symptom onset, since asymptomatic mutation carriers with a higher calorie and dairy intake develop HD symptoms at an earlier age [141]. Cognitive and physical lifestyle factors may also be influential, given that sedentary behaviour is associated with an earlier onset and greater severity of symptoms [142].

HD: bulk of the iceberg

Human neuroimaging and post-mortem studies show that impaired mitochondrial biology occurs early in the pathogenesis of HD [55]. PET studies have detected glucose hypometabolism in the striatum, which often occurs years before the clinical symptoms [45]. Phenotypically, striatal neuron mitochondria exhibit reduced numbers [143]. Striatal and cortical neuron mitochondria display a loss of balance between fusion and fission [143, 144], and striatal neurons in asymptomatic mutation carriers show decreased expression of the key mitogenesis regulator PGC-1α [145]. Functionally, ATP synthesis is decreased in the skeletal muscle of both asymptomatic and symptomatic mutation carriers [146]. There is also evidence of increased oxidative damage in the cerebral cortex [144], as well as calcium dysregulation in lymphoblasts [147]. Striatal neuron mitochondria demonstrate decreased enzyme activities in ETC complexes II–IV [148], which is accompanied by inhibited complex I activity in skeletal myocytes [149]. Moreover, cortical and skeletal muscle mitochondria exhibit abnormal features, such as unusually large, dense mitochondria with altered cristae and oxidative damage to their mtDNA [149–151]. Altogether, these multifaceted mitochondrial alterations would be expected to lead to a series of energetically costly adjustments, including compensatory hypermetabolism in the thalamus and cerebellum [152]. Despite these adjustments, impaired mitochondrial biology still ripples out at the level of the organism.

HD: tip of the iceberg

After years or decades of impaired mitochondrial biology, the tip emerges as HD, which is typically diagnosed in the setting of involuntary hyperkinetic movements (chorea) supported by confirmatory genetic testing [153]. These symptoms may be accompanied by neurodegenerative changes in the striatum and cerebral cortex, as well as biomarker evidence of the mutant HTT protein [154, 155]. However, many additional symptoms may accompany the hallmark choreiform symptoms, which include poor social cognition, irritability, depression, anxiety, apathy, psychosis, skeletal muscle wasting, weight loss, and heart failure [18]. Accordingly, neurodegenerative changes are present elsewhere in the nervous system, such as the thalamus, cerebellum, and brainstem [20]. Outside the nervous system, skeletal and cardiac myocytes show aberrations related to the expression of the mutant HTT protein [24].

Mitohormesis

In 1932, a biphasic response to harmful substances was described, called “hormesis” [156]. Hormesis captures the observation that high concentrations of harmful substances lead to cell damage, whereas low levels induce adaptive responses that improve the body’s defence mechanisms and resilience [157]. Hormesis is particularly applicable to the generation of ROS, which drive cellular damage and aging at high levels [158, 159], but at low levels stimulate an adaptive mitochondrial stress response that ultimately enhances lifespan [160–162]. Given that mitochondria generate the majority of intracellular ROS, the hormesis concept was later recharacterized as “mitohormesis”, which highlights mitochondria as central coordinators of hormesis [163]. Mitohormesis encapsulates the idea that exposing mitochondria to a challenging (but not excessive) stressor leads to a recalibration of mitochondrial biology that subsequently protects the organelles against higher, normally harmful exposures to similar stressors in the future [164, 165]. Common stressors linked to mitohormesis include environmental toxins, dietary factors, cognitive stimulation, physical exercise, extreme temperatures, and hypoxia [157, 166–168]. Most of human evolution has been characterized by a mitohormesis-activating lifestyle [169], whereas many aspects of the modern lifestyle compromise mitohormesis.

We propose that mitohormesis may be optimally activated by strategies that facilitate a balanced oscillation between challenging (but not excessive) stressor phases, which temporarily disrupt mitochondrial biology, and complete (but not excessive) recovery phases, which provide adequate time for mitochondria to repair and recalibrate prior to the next stressor (Table 1). Previous similar proposals have focused on the benefits of the stressor phase (such as diet and exercise) in activating mitohormesis, with little or no emphasis on the crucial role of the recovery phase in optimizing it. The perspective presented here expands the mitohormesis concept by emphasizing that it is optimally activated by a balanced oscillation between mitochondrial stressor and recovery phases, rather than relying on one phase over the other. By manipulating these phases to achieve an optimal balance, it may be possible to sustainably harness mitohormesis as a preventative and therapeutic measure for people at risk of, or suffering with, neurodegenerative disorders. Table 1 Strategies that activate mitohormesis, which is optimally activated by a balanced oscillation between mitochondrial stressor and recovery phases

Lifestyle factors	Stressor phase	Recovery phase	
Industrial toxins	Exposure

Transient, low-dose exposures to heavy metals, air pollutants, pesticides, and chemicals

	Non-exposure

Prolonged, near-zero dose exposures to heavy metals, air pollutants, pesticides, and chemicals

	
Dietary lifestyle	Feeding

Evolutionary hunter-gatherer diets (minimally processed, carbohydrate-restricted)

	Fasting

Fasting protocols (particularly intermittent fasting, coffee permitted)

	
Cognitive behaviours	Cognitive stimulation

Cognitive training, activities that demand sustained attention and promote engagement

	Sleep

Adequate sleep opportunity in a dedicated environment, sleep hygiene measures

	
Physical behaviours	Exercise

Relatively intensive, strength-based exercise sessions

	Deep rest

Contemplative practices (such as breathwork, mindfulness, and meditation), prioritizing sufficient rest and recovery from exercise and psychosocial engagement

	
Psychosocial behaviours	Psychosocial engagement

Social activities, networks, supports, and relationships

	

Industrial toxins

Over the last 250 years of the industrial age, humans have been increasingly exposed to a variety of heavy metals, air pollutants, pesticides, and chemicals [8]. In evolution, multicellular organisms were frequently exposed to selective pressure from toxic elements such as oxygen, iron, copper, manganese, and zinc [170]. However, these toxic exposures occurred over millions of years, which provided ample time for primitive organisms to evolve protective mechanisms. By contrast, the relatively abrupt human exposure to industry-derived toxins has not provided adequate evolutionary time for adaptation to occur. Many industrial toxins selectively target and elicit oxidative damage in mitochondria [49], which are vulnerable owing to a relative deficiency in DNA repair mechanisms [171]. Of particular concern are mitotoxicants with long half-lives, such as heavy metals and air particulate matter, which may not be removed from mitochondria [172]. Toxin-mediated mitochondrial damage facilitates an upsurge in ROS emission, which leads to a vicious cycle of ROS-induced ROS release and further damage [62]. Simultaneously, chronic exposure to these toxins does not provide mitochondria with sufficient time to repair and recalibrate, which might otherwise enable them to recover.

Although human studies demonstrate there may be no safe level for some industrial toxins [173], a non-linear dose–response is also observed, consistent with the activation of mitohormesis [166, 174]. Specifically, while low-dose exposures to certain toxins increase the risk of disease, the risk increase slows down, flattens out, or even decreases with increasing doses [169, 175]. Although these “challenging”, low-dose exposures often induce a degree of mitochondrial damage, this does not necessarily translate to the appearance of disease and can lead to benefits as mitochondria recover and adapt [166]. Importantly, this adaptive response is optimally activated by transient exposures and may be diminished by chronic exposure.

Interestingly, chronic exposure to near-zero doses of many industrial toxins may also lead to harmful effects on mitochondria [166]. This may be explained by the notion that chronic exposure to very low doses of toxins within a “sub-hormetic zone” may not sufficiently activate mitohormesis [169]. Even in the case of synthetic chemicals, an increased risk of disease has been associated with increasing doses within the sub-hormetic zone, but the risk flattens out as doses approach the hormetic zone. Again, a potentially important caveat to this observation is that some industrial toxins may be so highly toxic that no acceptable level exists [173]. Nonetheless, appreciable evidence indicates that attempting to maintain many industrial toxin exposures at near-zero levels may not be optimal for mitochondrial biology.

In the context of mitohormesis, unless a particular industrial toxin is proven to be highly toxic at any level, implementing public policies and personal behaviours aimed at balancing (1) transient, low-dose exposures (challenging, not excessive, stressor phases) with (2) prolonged, near-zero dose exposures (complete, not excessive, recovery phases) should be considered as a potential preventative and therapeutic strategy for neurodegenerative disorders.

Dietary lifestyle

Arguably, the most profound changes in lifestyle over the last 50 years have occurred in the content and frequency of the human diet, which is characterized by a high intake of processed, carbohydrate-rich foods combined with multiple daily meals and snacks [9]. The modern dietary lifestyle represents less than 1% of the 10,000 or so years that most humans lived under an agrarian lifestyle, which itself has existed for less than 1% of the 2–3 million years that humans evolved under a hunter-gatherer lifestyle characterized by wild (pre-agrarian, unprocessed) foods and frequent periods of food scarcity [176]. Broadly speaking, the repeated consumption of processed, carbohydrate-rich foods constitutes a series of excessive stressor phases that lead to frequent blood glucose spikes, an overwhelming supply of nicotinamide adenine dinucleotide intermediates, and electron “overflow” along the mitochondrial ETC [177, 178]. In turn, electron overflow leads to excess ROS emission, a downward spiral of ROS-induced ROS release, and further damage [62], which culminates in mitochondrial fragmentation [50]. Simultaneously, a daily ritual of multiple meals and snacks leads to a series of insufficient recovery phases, given that the brief time intervals between meals do not provide mitochondria with adequate time to repair, recalibrate, and recover.

During feeding periods, the glucose spikes (and their sequelae) can be mitigated by low-carbohydrate diets, which restrict carbohydrates and increase fat to at least 40% of energy intake, and particularly by ketogenic diets, which restrict carbohydrates even further and increase fat to at least 70% of energy intake [179]. Restricting carbohydrate intake leads to a series of “challenging” nutritional stressor phases characterized by fewer and less severe blood glucose spikes, which mitigates electron overflow along the mitochondrial ETC and generates fewer ROS. A growing body of theoretical and clinical evidence also indicates that ketogenic diets can “rescue” brain and mitochondrial energy metabolism by generating ketones [180], a superior energy source for neurons that elicits fewer ROS, circumvents brain insulin resistance, and increases the expression of neurotrophic factors [181, 182]. Numerous animal studies show that ketogenic diets can benefit mitochondrial biology by restoring ion channel function, replenishing TCA cycle intermediates, enhancing respiration, and exerting pleiotropic neuroprotective effects, all of which would be expected to benefit people with neurodegenerative disorders [183]. Consistent with these findings, human interventional trials indicate that modified ketogenic diets can improve cognition, function, and quality of life in people with AD [184–187], as well as the motor and non-motor symptoms of PD [188–191]. Although the interventional evidence in people with ALS and HD is currently limited to case studies, these studies also hint at benefits [192, 193]. Beyond carbohydrate-restricted diets, the Mediterranean diet, which is typically based on unprocessed foods, may be beneficial for people with neurodegenerative disorders [194]. However, it is important to recognize that the vast majority of supportive evidence for the Mediterranean diet is derived from observational studies rather than interventional trials [195].

Outside the feeding periods, the incorporation of dedicated intermittent fasting periods (12–48 h) can relieve the chronic nutritional overload [196]. Fasting deprives the ETC of electrons, which leads to reduced ROS emission and an enhanced mitochondrial capacity to repair and recalibrate [182]. Fasting also induces many additional mechanisms that may be beneficial in neurodegenerative disorders, including the generation of ketones, increased expression of neurotrophic factors, and the stimulation of mitogenesis and mitophagy. Interventional studies in animal models show that fasting induces many beneficial metabolic changes and can slow the neurodegenerative process, leading to improved functional outcomes [197]. Benefits are also documented in animal models of monogenic disorders such as HD, including enhanced mitochondrial biology and clearance of the mutant HTT protein [198]. Despite these enticing findings, fasting-based interventional studies in people with neurodegenerative disorders are rare and currently relegated to case studies [192, 193].

In the context of mitohormesis, growing evidence suggests that an evolutionary hunter-gatherer dietary lifestyle aimed at balancing (1) minimally-processed, carbohydrate-restricted feeding periods (challenging, not excessive, stressor phases) with (2) intermittent fasting protocols (complete, not excessive, recovery phases) should be considered as a preventative and therapeutic strategy for neurodegenerative disorders.

Cognitive, physical, and psychosocial behaviours

Significant changes in behaviour over the last 50 years have arisen in the setting of technological advances, which have undermined human exposure to a variety of authentic cognitive, physical, and psychosocial activities, as well as sleep and rest states. The human brain evolved over millions of years to learn, move, and interact within authentic environmental and social contexts, which cultivated positive psychosocial experiences associated with more abundant mitochondrial ETC proteins in the brain [199]. By contrast, the ease of living associated with technological advances in television, the internet, and digital media compromises the mitochondrial stressor phase. Simultaneously, chronic technology exposure disrupts natural sleep patterns and diverts bioenergetic resources away from natural resting states, which are essential for mitochondrial recovery [200, 201].

Preliminary evidence indicates that cognitive challenges can lead to physiological changes that may activate mitohormesis [168, 202]. Many studies indicate that environmental enrichment based on cognitive, sensory, and motor stimulation induces neuron remodelling and enhances cognitive and physical performance in animal models of AD, PD, ALS, and HD [203]. Interventional studies also show that cognitive stimulation leads to benefits in people with neurodegenerative disorders, which may be partially mediated by activated mitohormesis. A meta-analysis of 26 interventional studies found that multicomponent training, including lifestyle changes, enhances cognition in people with mild cognitive impairment [204]. A systematic review and meta-analysis of 15 interventional studies also discovered that playing board games preserves cognitive functions and brain structures in people with AD and dementia [205]. Furthermore, interventional studies demonstrate that multidisciplinary rehabilitation programs based on cognitive training, physical activities, and social events can lead to multiple cognitive benefits and reduce striatal and cortical atrophy in people with HD [206, 207].

Physical exercise can activate mitohormesis and improve many facets of mitochondrial biology [208]. In humans, even a single hour of challenging exercise induces significant ROS emission, oxidative damage, and mitochondrial impairments [209], including variable numbers of swollen mitochondria [210]. Following exercise, however, numerous cellular and mitochondrial adaptations occur, including anti-inflammatory, repair, and degradation processes [168, 211]. A wealth of interventional data indicates that exercise improves multiple outcome measures in people with neurodegenerative disorders, which may partly relate to the activation of mitohormesis. A systematic review of 28 randomized controlled trials found that intensive exercise performed over 2–3 days a week induces benefits in cognitive and physical function, functional independence, and neuropsychiatric symptoms in people with AD [212]. An updated systematic review of 33 randomized controlled trials demonstrated that intensive exercise leads to better functional capacity in PD [213]. Moreover, a systematic review of 7 randomized controlled trials showed that exercise enhances functional ability and pulmonary indices in ALS [214]. Furthermore, a review of 6 studies discovered that exercise induces benefits in cognition, motor symptoms, and mitochondrial content in HD [215]. Importantly, while insufficient exercise is a risk factor for many neurodegenerative disorders, excessive cardiovascular exercise (with insufficient recovery) can also lead to numerous adverse health outcomes [216], which may include an increased risk of developing ALS [113].

It has been suggested that mitochondria function as an intersection point within the body by sensing and translating psychosocial stressors into a range of biological modifications, including adaptive (or maladaptive) mitochondrial recalibrations [217]. Supportive evidence for this idea was provided by a recent systematic review of 23 animal studies, which showed that acute psychosocial stressors induce mitochondrial damage within hours, which in turn elicits a variety of protective mitochondrial recalibrations [218]. Conversely, chronic stress exposure facilitates maladaptive adjustments among mitochondria. Human observational studies also display an association between higher levels of social engagement and better late-life cognition [219], which may be partially mediated by activated mitohormesis. A systematic review of 39 observational and interventional studies found that a range of social activities, networks, supports, and relationships may improve cognitive function in older adults [220]. A smaller systematic review showed that social support interventions may reduce depression and benefit quality of life and self-esteem in AD [221].

Sleep has been described as a “mitorestorative” state that specifically protects and rejuvenates mitochondria [222]. Consistent with this hypothesis, sleep deprivation culminates in maladaptive metabolic and mitochondrial adjustments, including impaired neuronal ETC activity [223]. Sleep, by contrast, enhances the clearance of toxic metabolites from the brain, including ROS, as well as abnormal protein aggregates, such as amyloid-β [224]. Sleep also induces mitophagy, which keeps the mitochondrial pool healthy [225]. Human interventional studies show that better sleep leads to changes that would be expected to benefit people with neurodegenerative disorders, which may be partially mediated by enhanced mitochondrial recovery. A recent meta-analysis of 65 randomized controlled trials showed that improved sleep leads to better mental health, including improvements in depression, anxiety, rumination, stress, and psychosis [226].

Engaging in contemplative practices may facilitate a restorative state of “deep rest”, which channels energetic resources towards processes that optimize cellular function while diverting them away from energy-demanding stress states [201]. During a state of deep rest, energetic demands are low, which enables mitochondria to repair and recalibrate through mitogenesis and other restorative processes. A range of deep rest practices that would be expected to benefit people with neurodegenerative disorders may partly relate to enhanced mitochondrial recovery. A meta-analysis of 12 randomized controlled trials found that breathwork can be effective for mitigating stress and enhancing mental health [227]. A narrative review of 10 interventional studies also demonstrated that mindfulness or meditation may lead to less cognitive decline, a decrease in perceived stress, and positive changes in brain functional connectivity, volume, and blood flow in people with AD, dementia, or dementia-related memory conditions [228]. Moreover, a systematic review of 9 interventional studies discovered that mindfulness leads to cognitive benefits in PD [229].

In the context of mitohormesis, growing evidence indicates that an authentic lifestyle aimed at balancing (1) cognitive stimulation, exercise, and psychosocial engagement sessions (challenging, not excessive, stressor phases) with (2) dedicated sleep and deep rest practices (complete, not excessive, recovery phases) offers promise as a preventative and therapeutic strategy for neurodegenerative disorders. More research is required regarding their effectiveness.

Conclusions

In keeping with Ovid’s statement that obvious effects often have hidden causes, we must carefully consider the cascade of events that underlie neurodegenerative disorders. The longstanding split of these disorders based on their hallmark clinical, anatomical, and pathological features leads to the perception that they are focal neurological disorders amenable to targeted, suppressive treatments. Splitting is useful for diagnosis and management. However, treatments based on splitting alone have struggled to produce clinically meaningful outcomes. Using an alternative scientific framework, neurodegenerative disorders can be lumped by a shared feature of impaired mitochondrial biology. Lumping more accurately depicts these disorders as multisystemic disorders in need of multisystemic, restorative therapies. Since lumping emphasizes hidden causes rather than visible effects, it may get us further along the path of recognizing the modifiable etiological factors of neurodegeneration that are crucial for guiding prevention and therapy.

In this article, we have presented a conceptualization of neurodegenerative disorders as metabolic icebergs, which conveys the hallmark clinical, anatomical, and pathological features (tip) as late-stage effects of impaired mitochondrial biology (bulk), which in turn is induced by a suite of environmental and genetic factors (base). Mitohormesis-activating strategies can be sustainably harnessed to facilitate a balanced oscillation between mitochondrial stressor and recovery phases, leading to the repair, recalibration, and recovery of mitochondria throughout the body. Ultimately, we may find success in treating the rising tide of neurodegenerative disorders by addressing the hidden energetic and metabolic causes beneath the clinical waterline, rather than by focusing exclusively on the visible effects that naturally emerge, in time, above it.

Abbreviations

AD Alzheimer’s disease

PD Parkinson’s disease

ALS Amyotrophic lateral sclerosis

HD Huntington’s disease

ATP Adenosine triphosphate

ROS Reactive oxygen species

TCA Tricarboxylic acid

ETC Electron transport chain

mtDNA Mitochondrial DNA

PET Positron emission tomography

APOE4 Apolipoprotein E4

PRKN Parkin

PINK1 Phosphate and tensin homolog-induced kinase 1

PGC-1α Peroxisome proliferator-activated receptor-γ coactivator-1α

C9orf72 Chromosome 9 open reading frame 72

SOD1 Superoxide dismutase 1

FUS Fused in sarcoma

TDP-43 Transactive response DNA binding protein 43

HTT Huntingtin

Acknowledgements

MCLP respectfully acknowledges his AD, PD, ALS, and HD clinical trial participants (and their families). MP gratefully acknowledges support from Baszucki Group.

Author contributions

MCLP conceived the idea, performed the literature search, prepared the original tables and figures, wrote the first draft, and critically revised the manuscript. MP assisted with the literature search and critically revised the tables, figures, and manuscript. Both authors read and approved the final manuscript.

Funding

No funding was provided for this article.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
==== Refs
References

1. Ovid. Metamorphoses. Hugo Magnus (Ed.). Gotha (Germany). Friedr. Andr. Perthes. 1892.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 2018 392 1789 1858 10.1016/S0140-6736(18)32279-7 30496104
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858.30496104 10.1016/S0140-6736(18)32279-7
3. GBD 2019 Dementia Forecasting Collaborators Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 Lancet Public Health 2022 7 e105 e125 10.1016/S2468-2667(21)00249-8 34998485
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7:e105–25.34998485 10.1016/S2468-2667(21)00249-8
4. GBD 2016 Parkinson’s Disease Collaborators Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 2018 17 939 953 10.1016/S1474-4422(18)30295-3 30287051
GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53.30287051 10.1016/S1474-4422(18)30295-3
5. Longinetti E Fang F Epidemiology of amyotrophic lateral sclerosis: an update of recent literature Curr Opin Neurol 2019 32 771 776 10.1097/WCO.0000000000000730 31361627
Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771–6.31361627 10.1097/WCO.0000000000000730
6. Arthur KC Calvo A Price TR Geiger JT Chiò A Traynor BJ Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 Nat Commun 2016 7 12408 10.1038/ncomms12408 27510634
Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7:12408.27510634 10.1038/ncomms12408
7. Medina A Mahjoub Y Shaver L Pringsheim T Prevalence and incidence of Huntington’s disease: an updated systematic review and meta-analysis Mov Disord 2022 37 2327 2335 10.1002/mds.29228 36161673
Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington’s disease: an updated systematic review and meta-analysis. Mov Disord. 2022;37:2327–35.36161673 10.1002/mds.29228
8. Cannon JR Greenamyre JT The role of environmental exposures in neurodegeneration and neurodegenerative diseases Toxicol Sci 2011 124 225 250 10.1093/toxsci/kfr239 21914720
Cannon JR, Greenamyre JT. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci. 2011;124:225–50.21914720 10.1093/toxsci/kfr239
9. Phillips MC Metabolic strategies in healthcare: a new era Aging Dis 2022 13 655 672 10.14336/AD.2021.1018 35656107
Phillips MC. Metabolic strategies in healthcare: a new era. Aging Dis. 2022;13:655–72.35656107 10.14336/AD.2021.1018
10. Darwin Correspondence Project. “Letter No 2130”. https://www.darwinproject.ac.uk/letter/?docId=letters/DCP-LETT-2130.xml. Accessed 4 Mar 2024.
11. Greene JA Loscalzo J Putting the patient back together—social medicine, network medicine, and the limits of reductionism N Engl J Med 2017 377 2493 2499 10.1056/NEJMms1706744 29262277
Greene JA, Loscalzo J. Putting the patient back together—social medicine, network medicine, and the limits of reductionism. N Engl J Med. 2017;377:2493–9.29262277 10.1056/NEJMms1706744
12. Dugger BN Dickson DW Pathology of neurodegenerative diseases Cold Spring Harb Perspect Biol 2017 9 a028035 10.1101/cshperspect.a028035 28062563
Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9: a028035.28062563 10.1101/cshperspect.a028035
13. Raudino F Non-cognitive symptoms and related conditions in the Alzheimer’s disease: a literature review Neurol Sci 2013 34 1275 1282 10.1007/s10072-013-1424-7 23543394
Raudino F. Non-cognitive symptoms and related conditions in the Alzheimer’s disease: a literature review. Neurol Sci. 2013;34:1275–82.23543394 10.1007/s10072-013-1424-7
14. Ishii M Iadecola C Metabolic and non-cognitive manifestations of Alzheimer’s disease: the hypothalamus as both culprit and target of pathology Cell Metab 2015 22 761 776 10.1016/j.cmet.2015.08.016 26365177
Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer’s disease: the hypothalamus as both culprit and target of pathology. Cell Metab. 2015;22:761–76.26365177 10.1016/j.cmet.2015.08.016
15. Chaudhuri KR Healy DG Schapira AHV National Institute for Clinical Excellence Non-motor symptoms of Parkinson’s disease: diagnosis and management Lancet Neurol 2006 5 235 245 10.1016/S1474-4422(06)70373-8 16488379
Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–45.16488379 10.1016/S1474-4422(06)70373-8
16. Jellinger KA Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts Mov Disord 2012 27 8 30 10.1002/mds.23795 22081500
Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 2012;27:8–30.22081500 10.1002/mds.23795
17. Pender N Pinto-Grau M Hardiman O Cognitive and behavioural impairment in amyotrophic lateral sclerosis Curr Opin Neurol 2020 33 649 654 10.1097/WCO.0000000000000862 32833751
Pender N, Pinto-Grau M, Hardiman O. Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33:649–54.32833751 10.1097/WCO.0000000000000862
18. Eddy CM Parkinson EG Rickards HE Changes in mental state and behaviour in Huntington’s disease Lancet Psychiatry 2016 3 1079 1086 10.1016/S2215-0366(16)30144-4 27663851
Eddy CM, Parkinson EG, Rickards HE. Changes in mental state and behaviour in Huntington’s disease. Lancet Psychiatry. 2016;3:1079–86.27663851 10.1016/S2215-0366(16)30144-4
19. Geser F Brandmeir NJ Kwong LK Martinez-Lage M Elman L McCluskey L Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis Arch Neurol 2008 65 636 641 10.1001/archneur.65.5.636 18474740
Geser F, Brandmeir NJ, Kwong LK, Martinez-Lage M, Elman L, McCluskey L, et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol. 2008;65:636–41.18474740 10.1001/archneur.65.5.636
20. Rüb U Seidel K Heinsen H Vonsattel JP den Dunnen WF Korf HW Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain Brain Pathol 2016 26 726 740 10.1111/bpa.12426 27529157
Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW. Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol. 2016;26:726–40.27529157 10.1111/bpa.12426
21. Miklossy J Taddei K Martins R Escher G Kraftsik R Pillevuit O Alzheimer disease: curly fibers and tangles in organs other than brain J Neuropathol Exp Neurol 1999 58 803 814 10.1097/00005072-199908000-00003 10446805
Miklossy J, Taddei K, Martins R, Escher G, Kraftsik R, Pillevuit O, et al. Alzheimer disease: curly fibers and tangles in organs other than brain. J Neuropathol Exp Neurol. 1999;58:803–14.10446805 10.1097/00005072-199908000-00003
22. Djaldetti R Lev N Melamed E Lesions outside the CNS in Parkinson’s disease Mov Disord 2009 24 793 800 10.1002/mds.22172 19224610
Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson’s disease. Mov Disord. 2009;24:793–800.19224610 10.1002/mds.22172
23. Mori F Tada M Kon T Miki Y Tanji K Kurotaki H Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions Acta Neuropathol Commun 2019 7 165 10.1186/s40478-019-0824-1 31661037
Mori F, Tada M, Kon T, Miki Y, Tanji K, Kurotaki H, et al. Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions. Acta Neuropathol Commun. 2019;7:165.31661037 10.1186/s40478-019-0824-1
24. Melkani GC Huntington’s disease-induced cardiac disorders affect multiple cellular pathways React Oxyg Species (Apex) 2016 2 325 338 29963642
Melkani GC. Huntington’s disease-induced cardiac disorders affect multiple cellular pathways. React Oxyg Species (Apex). 2016;2:325–38.29963642
25. Jucker M Walker LC Alzheimer’s disease: from immunotherapy to immunoprevention Cell 2023 186 4260 4270 10.1016/j.cell.2023.08.021 37729908
Jucker M, Walker LC. Alzheimer’s disease: from immunotherapy to immunoprevention. Cell. 2023;186:4260–70.37729908 10.1016/j.cell.2023.08.021
26. Chatterjee D Kordower JH Immunotherapy in Parkinson’s disease: current status and future directions Neurobiol Dis 2019 132 104587 10.1016/j.nbd.2019.104587 31454546
Chatterjee D, Kordower JH. Immunotherapy in Parkinson’s disease: current status and future directions. Neurobiol Dis. 2019;132: 104587.31454546 10.1016/j.nbd.2019.104587
27. Howick J Koletsi D Ioannidis JPA Madigan C Pandis N Loef M Most healthcare interventions tested in cochrane reviews are not effective according to high quality evidence: a systematic review and meta-analysis J Clin Epidemiol 2022 148 160 169 10.1016/j.jclinepi.2022.04.017 35447356
Howick J, Koletsi D, Ioannidis JPA, Madigan C, Pandis N, Loef M, et al. Most healthcare interventions tested in cochrane reviews are not effective according to high quality evidence: a systematic review and meta-analysis. J Clin Epidemiol. 2022;148:160–9.35447356 10.1016/j.jclinepi.2022.04.017
28. Beal MF Mitochondria take center stage in aging and neurodegeneration Ann Neurol 2005 58 495 505 10.1002/ana.20624 16178023
Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495–505.16178023 10.1002/ana.20624
29. Klemmensen MM Borrowman SH Pearce C Pyles B Mitochondrial dysfunction in neurodegenerative disorders Neurotherapeutics 2024 21 e00292 10.1016/j.neurot.2023.10.002 38241161
Klemmensen MM, Borrowman SH, Pearce C, Pyles B. Mitochondrial dysfunction in neurodegenerative disorders. Neurotherapeutics. 2024;21: e00292.38241161 10.1016/j.neurot.2023.10.002
30. Manfredi G Beal MF The role of mitochondria in the pathogenesis of neurodegenerative diseases CNS Spectr 2000 10 426 472
Manfredi G, Beal MF. The role of mitochondria in the pathogenesis of neurodegenerative diseases. CNS Spectr. 2000;10:426–72.
31. Monzel AS Enríquez JA Picard M Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction Nat Metab 2023 5 546 562 10.1038/s42255-023-00783-1 37100996
Monzel AS, Enríquez JA, Picard M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. Nat Metab. 2023;5:546–62.37100996 10.1038/s42255-023-00783-1
32. Picard M Shirihai OS Mitochondrial signal transduction Cell Metab 2022 34 1620 1653 10.1016/j.cmet.2022.10.008 36323233
Picard M, Shirihai OS. Mitochondrial signal transduction. Cell Metab. 2022;34:1620–53.36323233 10.1016/j.cmet.2022.10.008
33. Martínez-Reyes I Chandel NS Mitochondrial TCA cycle metabolites control physiology and disease Nat Commun 2020 11 102 10.1038/s41467-019-13668-3 31900386
Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102.31900386 10.1038/s41467-019-13668-3
34. Santos JH Mitochondria signaling to the epigenome: a novel role for an old organelle Free Radic Biol Med 2021 170 59 69 10.1016/j.freeradbiomed.2020.11.016 33271282
Santos JH. Mitochondria signaling to the epigenome: a novel role for an old organelle. Free Radic Biol Med. 2021;170:59–69.33271282 10.1016/j.freeradbiomed.2020.11.016
35. Fecher C Trovò L Müller SA Snaidero N Wettmarshausen J Heink S Cell-type-specific profiling of brain mitochondria reveals functional and molecular diversity Nat Neurosci 2019 10 1731 1742 10.1038/s41593-019-0479-z
Fecher C, Trovò L, Müller SA, Snaidero N, Wettmarshausen J, Heink S, et al. Cell-type-specific profiling of brain mitochondria reveals functional and molecular diversity. Nat Neurosci. 2019;10:1731–42.10.1038/s41593-019-0479-z
36. Mosharov EV Rosenberg AM Monzel AS Osto CA Stiles L Rosoklija GB A human brain map of mitochondrial respiratory capacity and diversity bioRxiv 2024 10.1101/2024.03.05.583623 38496679
Mosharov EV, Rosenberg AM, Monzel AS, Osto CA, Stiles L, Rosoklija GB, et al. A human brain map of mitochondrial respiratory capacity and diversity. bioRxiv. 2024. 10.1101/2024.03.05.583623.38496679 10.1101/2024.03.05.583623
37. Rausser S Trumpff C McGill MA Junker A Wang W Ho S Mitochondrial phenotypes in purified human immune cell subtypes and cell mixtures Elife 2021 10 e70899 10.7554/eLife.70899 34698636
Rausser S, Trumpff C, McGill MA, Junker A, Wang W, Ho S, et al. Mitochondrial phenotypes in purified human immune cell subtypes and cell mixtures. Elife. 2021;10: e70899.34698636 10.7554/eLife.70899
38. Rosenberg AM Saggar M Monzel AS Devine J Rogu P Limoges A Brain mitochondrial diversity and network organization predict anxiety-like behavior in male mice Nat Commun 2023 14 4726 10.1038/s41467-023-39941-0 37563104
Rosenberg AM, Saggar M, Monzel AS, Devine J, Rogu P, Limoges A, et al. Brain mitochondrial diversity and network organization predict anxiety-like behavior in male mice. Nat Commun. 2023;14:4726.37563104 10.1038/s41467-023-39941-0
39. Naviaux RK Mitochondrial and metabolic features of salugenesis and the healing cycle Mitochondrion 2023 70 131 163 10.1016/j.mito.2023.04.003 37120082
Naviaux RK. Mitochondrial and metabolic features of salugenesis and the healing cycle. Mitochondrion. 2023;70:131–63.37120082 10.1016/j.mito.2023.04.003
40. Pereira JLB Downes A Gorgulho A Patel V Malkasian D De Salles A Alzheimer’s disease: the role for neurosurgery Surg Neurol Int 2014 5 S385 S390 10.4103/2152-7806.140191 25289167
Pereira JLB, Downes A, Gorgulho A, Patel V, Malkasian D, De Salles A. Alzheimer’s disease: the role for neurosurgery. Surg Neurol Int. 2014;5:S385–90.25289167 10.4103/2152-7806.140191
41. Sharma VD Patel M Miocinovic S Surgical treatment of Parkinson’s disease: devices and lesion approaches Neurotherapeutics 2020 17 1525 1538 10.1007/s13311-020-00939-x 33118132
Sharma VD, Patel M, Miocinovic S. Surgical treatment of Parkinson’s disease: devices and lesion approaches. Neurotherapeutics. 2020;17:1525–38.33118132 10.1007/s13311-020-00939-x
42. Cunnane S Nugent S Roy M Courchesne-Loyer A Croteau E Tremblay S Brain fuel metabolism, aging, and Alzheimer’s disease Nutrition 2011 27 3 20 10.1016/j.nut.2010.07.021 21035308
Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, et al. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition. 2011;27:3–20.21035308 10.1016/j.nut.2010.07.021
43. Strafella AP Bohnen NI Perlmutter JS Eidelberg D Pavese N Eimeren TV Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: new imaging frontiers Mov Disord 2017 32 181 192 10.1002/mds.26907 28150432
Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Eimeren TV, et al. Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: new imaging frontiers. Mov Disord. 2017;32:181–92.28150432 10.1002/mds.26907
44. Pagani M Chiò A Valentini MC Öberg J Nobili F Calvo A Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis Neurology 2014 83 1067 1074 10.1212/WNL.0000000000000792 25122207
Pagani M, Chiò A, Valentini MC, Öberg J, Nobili F, Calvo A, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067–74.25122207 10.1212/WNL.0000000000000792
45. López-Mora DA Camacho V Pérez-Pérez J Martínez-Horta S Fernández A Sampedro F Striatal hypometabolism in premanifest and manifest Huntington’s disease patients Eur J Nucl Med Mol Imaging 2016 43 2183 2189 10.1007/s00259-016-3445-y 27349245
López-Mora DA, Camacho V, Pérez-Pérez J, Martínez-Horta S, Fernández A, Sampedro F, et al. Striatal hypometabolism in premanifest and manifest Huntington’s disease patients. Eur J Nucl Med Mol Imaging. 2016;43:2183–9.27349245 10.1007/s00259-016-3445-y
46. Stevenson R Samokhina E Rossetti I Morley JW Buskila Y Neuromodulation of glial function during neurodegeneration Front Cell Neurosci 2020 14 278 10.3389/fncel.2020.00278 32973460
Stevenson R, Samokhina E, Rossetti I, Morley JW, Buskila Y. Neuromodulation of glial function during neurodegeneration. Front Cell Neurosci. 2020;14:278.32973460 10.3389/fncel.2020.00278
47. Tian Q Bilgel M Walker KA Moghekar AR Fishbein KW Spencer RG Skeletal muscle mitochondrial function predicts cognitive impairment and is associated with biomarkers of Alzheimer’s disease and neurodegeneration Alzheimer’s Dement 2023 19 4436 4445 10.1002/alz.13388 37530130
Tian Q, Bilgel M, Walker KA, Moghekar AR, Fishbein KW, Spencer RG, et al. Skeletal muscle mitochondrial function predicts cognitive impairment and is associated with biomarkers of Alzheimer’s disease and neurodegeneration. Alzheimer’s Dement. 2023;19:4436–45.37530130 10.1002/alz.13388
48. Landin S Hagenfeldt L Saltin B Wahren J Muscle metabolism during exercise in patients with Parkinson's disease Clin Sci Mol Med 1974 47 493 506 4279795
Landin S, Hagenfeldt L, Saltin B, Wahren J. Muscle metabolism during exercise in patients with Parkinson’s disease. Clin Sci Mol Med. 1974;47:493–506.4279795
49. Meyer JN Leung MCK Rooney JP Sendoel A Hengartner MO Kisby GE Mitochondria as a target of environmental toxicants Toxicol Sci 2013 134 1 17 10.1093/toxsci/kft102 23629515
Meyer JN, Leung MCK, Rooney JP, Sendoel A, Hengartner MO, Kisby GE, et al. Mitochondria as a target of environmental toxicants. Toxicol Sci. 2013;134:1–17.23629515 10.1093/toxsci/kft102
50. Picard M Turnbull DM Linking the metabolic state and mitochondrial DNA in chronic disease, health, and aging Diabetes 2013 62 672 678 10.2337/db12-1203 23431006
Picard M, Turnbull DM. Linking the metabolic state and mitochondrial DNA in chronic disease, health, and aging. Diabetes. 2013;62:672–8.23431006 10.2337/db12-1203
51. Picard M McEwen BS Psychological stress and mitochondria: a conceptual framework Psychosom Med 2018 80 126 140 10.1097/PSY.0000000000000544 29389735
Picard M, McEwen BS. Psychological stress and mitochondria: a conceptual framework. Psychosom Med. 2018;80:126–40.29389735 10.1097/PSY.0000000000000544
52. Weidling IW Swerdlow RH Mitochondria in Alzheimer’s disease and their potential role in Alzheimer’s proteostasis Exp Neurol 2020 330 113321 10.1016/j.expneurol.2020.113321 32339611
Weidling IW, Swerdlow RH. Mitochondria in Alzheimer’s disease and their potential role in Alzheimer’s proteostasis. Exp Neurol. 2020;330: 113321.32339611 10.1016/j.expneurol.2020.113321
53. Scarffe LA Stevens DA Dawson VL Dawson TM Parkin and PINK1: much more than mitophagy Trends Neurosci 2014 37 315 324 10.1016/j.tins.2014.03.004 24735649
Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neurosci. 2014;37:315–24.24735649 10.1016/j.tins.2014.03.004
54. Smith EF Shaw PJ De Vos KJ The role of mitochondria in amyotrophic lateral sclerosis Neurosci Lett 2019 710 132933 10.1016/j.neulet.2017.06.052 28669745
Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710: 132933.28669745 10.1016/j.neulet.2017.06.052
55. Dai Y Wang H Lian A Li J Zhao G Hu S A comprehensive perspective of Huntington’s disease and mitochondrial dysfunction Mitochondrion 2023 70 8 19 10.1016/j.mito.2023.03.001 36906250
Dai Y, Wang H, Lian A, Li J, Zhao G, Hu S, et al. A comprehensive perspective of Huntington’s disease and mitochondrial dysfunction. Mitochondrion. 2023;70:8–19.36906250 10.1016/j.mito.2023.03.001
56. Yegambaram M Manivannan B Beach TG Halden RU Role of environmental contaminants in the etiology of Alzheimer’s disease: a review Curr Alzheimer Res 2015 12 116 146 10.2174/1567205012666150204121719 25654508
Yegambaram M, Manivannan B, Beach TG, Halden RU. Role of environmental contaminants in the etiology of Alzheimer’s disease: a review. Curr Alzheimer Res. 2015;12:116–46.25654508 10.2174/1567205012666150204121719
57. Goldman SM Environmental toxins and Parkinson’s disease Annu Rev Pharmacol Toxicol 2014 54 141 164 10.1146/annurev-pharmtox-011613-135937 24050700
Goldman SM. Environmental toxins and Parkinson’s disease. Annu Rev Pharmacol Toxicol. 2014;54:141–64.24050700 10.1146/annurev-pharmtox-011613-135937
58. Ingre C Roos PM Piehl F Kamel F Fang F Risk factors for amyotrophic lateral sclerosis Clin Epidemiol 2015 7 181 193 25709501
Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181–93.25709501
59. Beal MF Aging, energy, and oxidative stress in neurodegenerative diseases Ann Neurol 1995 38 357 366 10.1002/ana.410380304 7668820
Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol. 1995;38:357–66.7668820 10.1002/ana.410380304
60. Nunomura A Perry G Aliev G Hirai K Takeda A Balraj EK Oxidative damage is the earliest event in Alzheimer disease J Neuropathol Exp Neurol 2001 60 759 767 10.1093/jnen/60.8.759 11487050
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759–67.11487050 10.1093/jnen/60.8.759
61. Turrens JF Mitochondrial formation of reactive oxygen species J Physiol 2003 15 335 344 10.1113/jphysiol.2003.049478
Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;15:335–44.10.1113/jphysiol.2003.049478
62. Zorov DB Filburn CR Klotz LO Zweier JL Sollott SJ Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes J Exp Med 2000 192 1001 1014 10.1084/jem.192.7.1001 11015441
Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001–14.11015441 10.1084/jem.192.7.1001
63. Adamu A Li S Gao F Xue G The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets Front Aging Neurosci 2024 16 1347987 10.3389/fnagi.2024.1347987 38681666
Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024;16:1347987.38681666 10.3389/fnagi.2024.1347987
64. Teleanu DM Niculescu A Lungu II Radu CI Vladâcenco O Roza E An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases Int J Mol Sci 2022 23 5938 10.3390/ijms23115938 35682615
Teleanu DM, Niculescu A, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci. 2022;23:5938.35682615 10.3390/ijms23115938
65. Audano M Schneider A Mitro N Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration J Neurochem 2018 147 291 309 10.1111/jnc.14471 29804302
Audano M, Schneider A, Mitro N. Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration. J Neurochem. 2018;147:291–309.29804302 10.1111/jnc.14471
66. Wang W Yin J Ma X Zhao F Siedlak SL Wang Z Inhibition of mitochondrial fragmentation protects against Alzheimer’s disease in rodent model Human Mol Genet 2017 26 4118 4131 10.1093/hmg/ddx299 28973308
Wang W, Yin J, Ma X, Zhao F, Siedlak SL, Wang Z, et al. Inhibition of mitochondrial fragmentation protects against Alzheimer’s disease in rodent model. Human Mol Genet. 2017;26:4118–31.28973308 10.1093/hmg/ddx299
67. Du F Yu Q Kanaan NM Yan SS Mitochondrial oxidative stress contributes to the pathological aggregation and accumulation of tau oligomers in Alzheimer's disease Hum Mol Genet 2022 31 2498 2507 10.1093/hmg/ddab363 35165721
Du F, Yu Q, Kanaan NM, Yan SS. Mitochondrial oxidative stress contributes to the pathological aggregation and accumulation of tau oligomers in Alzheimer’s disease. Hum Mol Genet. 2022;31:2498–507.35165721 10.1093/hmg/ddab363
68. Burbulla LF Song P Mazzulli JR Zampese E Wong YC Jeon S Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease Science 2017 357 1255 1261 10.1126/science.aam9080 28882997
Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science. 2017;357:1255–61.28882997 10.1126/science.aam9080
69. Won SK Fong R Butler N Sanchez J Zhang Y Wong C Neuronal oxidative stress promotes α-synuclein aggregation in vivo Antioxidants 2022 11 2466 10.3390/antiox11122466 36552674
Won SK, Fong R, Butler N, Sanchez J, Zhang Y, Wong C, et al. Neuronal oxidative stress promotes α-synuclein aggregation in vivo. Antioxidants. 2022;11:2466.36552674 10.3390/antiox11122466
70. Ayala V Granado-Serrano AB Cacabelos D Naudí A Ilieva E Boada J Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS Acta Neuropathol 2011 122 259 270 10.1007/s00401-011-0850-y 21706176
Ayala V, Granado-Serrano AB, Cacabelos D, Naudí A, Ilieva E, Boada J, et al. Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathol. 2011;122:259–70.21706176 10.1007/s00401-011-0850-y
71. Iguchi Y Katsuno M Takagi S Ishigaki S Niwa J Hasegawa M Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies Neurobiol Dis 2012 45 862 870 10.1016/j.nbd.2011.12.002 22198567
Iguchi Y, Katsuno M, Takagi S, Ishigaki S, Niwa J, Hasegawa M. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol Dis. 2012;45:862–70.22198567 10.1016/j.nbd.2011.12.002
72. Abramov AY Berezhnov AV Fedotova EI Zinchenko VP Dolgacheva LP Interaction of misfolded proteins and mitochondria in neurodegenerative disorders Biochem Soc Trans 2017 45 1025 1033 10.1042/BST20170024 28733489
Abramov AY, Berezhnov AV, Fedotova EI, Zinchenko VP, Dolgacheva LP. Interaction of misfolded proteins and mitochondria in neurodegenerative disorders. Biochem Soc Trans. 2017;45:1025–33.28733489 10.1042/BST20170024
73. Aziz NA van der Marck MA Pijl H Rikkert MGMO Bloem BR Roos RAC Weight loss in neurodegenerative disorders J Neurol 2009 255 1872 1880 10.1007/s00415-009-0062-8
Aziz NA, van der Marck MA, Pijl H, Rikkert MGMO, Bloem BR, Roos RAC. Weight loss in neurodegenerative disorders. J Neurol. 2009;255:1872–80.10.1007/s00415-009-0062-8
74. Silva MVF Loures CMG Alves LCV de Souza LC Borges KBG Carvalho MG Alzheimer’s disease: risk factors and potentially protective measures J Biomed Sci 2019 26 33 10.1186/s12929-019-0524-y 31072403
Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MG. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26:33.31072403 10.1186/s12929-019-0524-y
75. Livingston G Huntley J Sommerlad A Ames D Ballard C Banerjee S Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Lancet 2020 396 413 446 10.1016/S0140-6736(20)30367-6 32738937
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413–46.32738937 10.1016/S0140-6736(20)30367-6
76. Mahley RW Apolipoprotein E4 targets mitochondria and the mitochondria-associated membrane complex in neuropathology, including Alzheimer’s disease Curr Opin Neurobiol 2023 79 102684 10.1016/j.conb.2023.102684 36753858
Mahley RW. Apolipoprotein E4 targets mitochondria and the mitochondria-associated membrane complex in neuropathology, including Alzheimer’s disease. Curr Opin Neurobiol. 2023;79: 102684.36753858 10.1016/j.conb.2023.102684
77. Devi L Prabhu BM Galati DF Avadhani NG Anandatheerthavarada HK Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain Is associated with mitochondrial dysfunction J Neurosci 2006 26 9057 9068 10.1523/JNEUROSCI.1469-06.2006 16943564
Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain Is associated with mitochondrial dysfunction. J Neurosci. 2006;26:9057–68.16943564 10.1523/JNEUROSCI.1469-06.2006
78. Toglia P Cheung K Mak DD Ullah G Impaired mitochondrial function due to familial Alzheimer’s disease-causing presenilins mutants via Ca(2+) disruptions Cell Calcium 2016 59 240 250 10.1016/j.ceca.2016.02.013 26971122
Toglia P, Cheung K, Mak DD, Ullah G. Impaired mitochondrial function due to familial Alzheimer’s disease-causing presenilins mutants via Ca(2+) disruptions. Cell Calcium. 2016;59:240–50.26971122 10.1016/j.ceca.2016.02.013
79. Swerdlow RH Mitochondria and mitochondrial cascades in Alzheimer’s disease J Alzheimers Dis 2018 62 1403 1416 10.3233/JAD-170585 29036828
Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis. 2018;62:1403–16.29036828 10.3233/JAD-170585
80. Steen E Terry BM Rivera EJ Cannon JL Neely TR Ravares R Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—Is this type 3 diabetes? J Alzheimers Dis 2005 7 63 80 10.3233/JAD-2005-7107 15750215
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Ravares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—Is this type 3 diabetes? J Alzheimers Dis. 2005;7:63–80.15750215 10.3233/JAD-2005-7107
81. Hirai K Aliev G Nunomura A Fujioka H Russell RL Atwood CS Mitochondrial abnormalities in Alzheimer’s disease J Neurosci 2001 21 3017 3023 10.1523/JNEUROSCI.21-09-03017.2001 11312286
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci. 2001;21:3017–23.11312286 10.1523/JNEUROSCI.21-09-03017.2001
82. Pickett EK Rose J McCrory C McKenzie C King D Smith C Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer’s disease Acta Neuropathol 2018 136 747 757 10.1007/s00401-018-1903-2 30191401
Pickett EK, Rose J, McCrory C, McKenzie C, King D, Smith C, et al. Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer’s disease. Acta Neuropathol. 2018;136:747–57.30191401 10.1007/s00401-018-1903-2
83. Manczak M Calkins MJ Reddy PH Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage Hum Mol Genet 2011 20 2495 2509 10.1093/hmg/ddr139 21459773
Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Hum Mol Genet. 2011;20:2495–509.21459773 10.1093/hmg/ddr139
84. Yu Q Fang D Swerdlow RH Yu H Chen JX Yan SS Antioxidants rescue mitochondrial transport in differentiated Alzheimer’s disease trans-mitochondrial cybrid cells J Alzheimers Dis 2016 54 679 690 10.3233/JAD-160532 27567872
Yu Q, Fang D, Swerdlow RH, Yu H, Chen JX, Yan SS. Antioxidants rescue mitochondrial transport in differentiated Alzheimer’s disease trans-mitochondrial cybrid cells. J Alzheimers Dis. 2016;54:679–90.27567872 10.3233/JAD-160532
85. Fang EF Hou Y Palikaras K Adriaanse BA Kerr JS Yang B Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease Nat Neurosci 2019 22 401 412 10.1038/s41593-018-0332-9 30742114
Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat Neurosci. 2019;22:401–12.30742114 10.1038/s41593-018-0332-9
86. Terni B Boada J Portero-Otin M Pamplona R Ferrer I Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer’s disease pathology Brain Pathol 2010 20 222 233 10.1111/j.1750-3639.2009.00266.x 19298596
Terni B, Boada J, Portero-Otin M, Pamplona R, Ferrer I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer’s disease pathology. Brain Pathol. 2010;20:222–33.19298596 10.1111/j.1750-3639.2009.00266.x
87. Supnet C Bezprozvanny I Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer’s disease J Alzheimers Dis 2010 20 Suppl 2 S487 S498 10.3233/JAD-2010-100306 20413848
Supnet C, Bezprozvanny I. Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer’s disease. J Alzheimers Dis. 2010;20(Suppl 2):S487–98.20413848 10.3233/JAD-2010-100306
88. Mutisya EM Bowling AC Beal MF Cortical cytochrome oxidase activity is reduced in Alzheimer’s disease J Neurochem 1994 63 2179 2184 10.1046/j.1471-4159.1994.63062179.x 7964738
Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer’s disease. J Neurochem. 1994;63:2179–84.7964738 10.1046/j.1471-4159.1994.63062179.x
89. Baloyannis SJ Mitochondrial alterations in Alzheimer’s disease J Alzheimers Dis 2006 9 119 126 10.3233/JAD-2006-9204 16873959
Baloyannis SJ. Mitochondrial alterations in Alzheimer’s disease. J Alzheimers Dis. 2006;9:119–26.16873959 10.3233/JAD-2006-9204
90. McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 2011 7 263 269 10.1016/j.jalz.2011.03.005 21514250
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.21514250 10.1016/j.jalz.2011.03.005
91. Henriques AD Benedet AL Camargos EF Rosa-Neto P Nóbrega OT Fluid and imaging biomarkers for Alzheimer’s disease: where we stand and where to head to Exp Gerontol 2018 107 169 177 10.1016/j.exger.2018.01.002 29307736
Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, Nóbrega OT. Fluid and imaging biomarkers for Alzheimer’s disease: where we stand and where to head to. Exp Gerontol. 2018;107:169–77.29307736 10.1016/j.exger.2018.01.002
92. Betarbet R Sherer TB MacKenzie G Garcia-Osuna M Panov AV Greenamayre JT Chronic systemic pesticide exposure reproduces features of Parkinson’s disease Nat Neurosci 2000 3 1301 1306 10.1038/81834 11100151
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamayre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3:1301–6.11100151 10.1038/81834
93. Langston JW Ballard P Tetrud JW Irwin I Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 1983 219 979 980 10.1126/science.6823561 6823561
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–80.6823561 10.1126/science.6823561
94. Mischley LK Lau RC Bennett RD Role of diet and nutritional supplements in Parkinson’s disease progression Oxid Med Cell Longev 2017 2017 6405278 10.1155/2017/6405278 29081890
Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson’s disease progression. Oxid Med Cell Longev. 2017;2017:6405278.29081890 10.1155/2017/6405278
95. Belvisi D Pellicciari R Fabbrini G Tinazzi M Berardelli A Defazio G Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson’s disease: What do prospective studies suggest? Neurobiol Dis 2020 134 104671 10.1016/j.nbd.2019.104671 31706021
Belvisi D, Pellicciari R, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson’s disease: What do prospective studies suggest? Neurobiol Dis. 2020;134: 104671.31706021 10.1016/j.nbd.2019.104671
96. Terracciano A Luchetti M Karakose S Stephan Y Sutin AR Loneliness and risk of Parkinson disease JAMA Neurol 2023 80 1138 1144 10.1001/jamaneurol.2023.3382 37782489
Terracciano A, Luchetti M, Karakose S, Stephan Y, Sutin AR. Loneliness and risk of Parkinson disease. JAMA Neurol. 2023;80:1138–44.37782489 10.1001/jamaneurol.2023.3382
97. Kitada T Asakawa S Hattori N Matsumine H Yamamura Y Minoshima S Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 1998 392 605 608 10.1038/33416 9560156
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–8.9560156 10.1038/33416
98. Valente EM Abou-Sleiman PM Caputo V Muqit MMK Harvey K Gispert S Hereditary early-onset Parkinson’s disease caused by mutations in PINK1 Science 2004 304 1158 1160 10.1126/science.1096284 15087508
Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158–60.15087508 10.1126/science.1096284
99. Bose A Beal MF Mitochondrial dysfunction in Parkinson’s disease J Neurochem 2016 139 Suppl 1 216 231 10.1111/jnc.13731 27546335
Bose A, Beal MF. Mitochondrial dysfunction in Parkinson’s disease. J Neurochem. 2016;139(Suppl 1):216–31.27546335 10.1111/jnc.13731
100. Esteves AR Gozes I Cardoso SM The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson’s disease Biochim Biophys Acta 2014 1842 7 21 10.1016/j.bbadis.2013.10.003 24120997
Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson’s disease. Biochim Biophys Acta. 2014;1842:7–21.24120997 10.1016/j.bbadis.2013.10.003
101. Zheng B Liao Z Locascio JJ Lesniak KA Roderick SS Watt ML PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease Sci Transl Med 2010 2 52ra73 10.1126/scitranslmed.3001059 20926834
Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2: 52ra73.20926834 10.1126/scitranslmed.3001059
102. Davey GP Peuchen S Clark JB Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration J Biol Chem 1998 273 12753 12757 10.1074/jbc.273.21.12753 9582300
Davey GP, Peuchen S, Clark JB. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem. 1998;273:12753–7.9582300 10.1074/jbc.273.21.12753
103. Isobe C Abe T Terayama Y Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process Neurosci Lett 2010 469 159 163 10.1016/j.neulet.2009.11.065 19944739
Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett. 2010;469:159–63.19944739 10.1016/j.neulet.2009.11.065
104. Schapira AHV Cooper JM Dexter D Cark JB Jenner P Marsden CD Mitochondrial complex I deficiency in Parkinson’s disease J Neurochem 1990 54 823 827 10.1111/j.1471-4159.1990.tb02325.x 2154550
Schapira AHV, Cooper JM, Dexter D, Cark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990;54:823–7.2154550 10.1111/j.1471-4159.1990.tb02325.x
105. Bindoff LA Birch-Machin MA Cartlidge NE Parker WD Jr Turnbull DM Respiratory chain abnormalities in skeletal muscle from patients with Parkinson’s disease J Neurol Sci 1991 104 203 208 10.1016/0022-510X(91)90311-T 1658241
Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD Jr, Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson’s disease. J Neurol Sci. 1991;104:203–8.1658241 10.1016/0022-510X(91)90311-T
106. Parker WD Jr Boyson SJ Parks JK Abnormalities of the electron transport chain in idiopathic Parkinson’s disease Ann Neurol 1989 26 719 723 10.1002/ana.410260606 2557792
Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol. 1989;26:719–23.2557792 10.1002/ana.410260606
107. Trimmer PA Swerdlow RH Parks JK Keeney P Bennett JP Jr Miller SW Abnormal mitochondrial morphology in sporadic Parkinson’s and Alzheimer's disease cybrid cell lines Exp Neurol 2000 162 37 50 10.1006/exnr.2000.7333 10716887
Trimmer PA, Swerdlow RH, Parks JK, Keeney P, Bennett JP Jr, Miller SW, et al. Abnormal mitochondrial morphology in sporadic Parkinson’s and Alzheimer’s disease cybrid cell lines. Exp Neurol. 2000;162:37–50.10716887 10.1006/exnr.2000.7333
108. Kraytsberg Y Kudryavtseva E McKee AC Geula C Kowall NW Khrapko K Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons Nat Genet 2006 38 518 520 10.1038/ng1778 16604072
Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet. 2006;38:518–20.16604072 10.1038/ng1778
109. Postuma RB Berg D Stern M Poewe W Olanow CW Oertel W MDS clinical diagnostic criteria for Parkinson’s disease Mov Disord 2015 30 1591 1601 10.1002/mds.26424 26474316
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.26474316 10.1002/mds.26424
110. Algarni MA Stoessl AJ The role of biomarkers and imaging in Parkinson’s disease Expert Rev Neurother 2016 16 187 203 10.1586/14737175.2016.1135056 26829357
Algarni MA, Stoessl AJ. The role of biomarkers and imaging in Parkinson’s disease. Expert Rev Neurother. 2016;16:187–203.26829357 10.1586/14737175.2016.1135056
111. Vergara X Kheifets L Greenland S Oksuzyan S Cho Y Mezei G Occupational exposure to extremely low-frequency magnetic fields and neurodegenerative disease: a meta-analysis J Occup Environ Med 2013 55 135 146 10.1097/JOM.0b013e31827f37f8 23389409
Vergara X, Kheifets L, Greenland S, Oksuzyan S, Cho Y, Mezei G. Occupational exposure to extremely low-frequency magnetic fields and neurodegenerative disease: a meta-analysis. J Occup Environ Med. 2013;55:135–46.23389409 10.1097/JOM.0b013e31827f37f8
112. Armon C Smoking may be considered an established risk factor for sporadic ALS Neurology 2009 73 1693 1698 10.1212/WNL.0b013e3181c1df48 19917993
Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. 2009;73:1693–8.19917993 10.1212/WNL.0b013e3181c1df48
113. Pupillo E Messina P Giussani G Logroscino G Zoccolella S Chiò A Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study Ann Neurol 2014 75 708 716 10.1002/ana.24150 24706338
Pupillo E, Messina P, Giussani G, Logroscino G, Zoccolella S, Chiò A, et al. Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study. Ann Neurol. 2014;75:708–16.24706338 10.1002/ana.24150
114. Mattsson P Lönnstedt I Nygren I Askmark H Physical fitness, but not muscle strength, is a risk factor for death in amyotrophic lateral sclerosis at an early age J Neurol Neurosurg Psychiatry 2012 83 390 394 10.1136/jnnp.2010.218982 20852312
Mattsson P, Lönnstedt I, Nygren I, Askmark H. Physical fitness, but not muscle strength, is a risk factor for death in amyotrophic lateral sclerosis at an early age. J Neurol Neurosurg Psychiatry. 2012;83:390–4.20852312 10.1136/jnnp.2010.218982
115. Lopez-Gonzalez R Lu Y Gendron TF Karydas A Tran H Yang D Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons Neuron 2016 92 383 391 10.1016/j.neuron.2016.09.015 27720481
Lopez-Gonzalez R, Lu Y, Gendron TF, Karydas A, Tran H, Yang D, et al. Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92:383–91.27720481 10.1016/j.neuron.2016.09.015
116. Kong J Xu Z Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1 J Neurosci 1998 18 3241 3250 10.1523/JNEUROSCI.18-09-03241.1998 9547233
Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998;18:3241–50.9547233 10.1523/JNEUROSCI.18-09-03241.1998
117. Deng J Yang M Chen Y Chen X Liu J Sun S FUS Interacts with HSP60 to promote mitochondrial damage PLoS Genet 2015 11 e1005357 10.1371/journal.pgen.1005357 26335776
Deng J, Yang M, Chen Y, Chen X, Liu J, Sun S, et al. FUS Interacts with HSP60 to promote mitochondrial damage. PLoS Genet. 2015;11: e1005357.26335776 10.1371/journal.pgen.1005357
118. Conte A Lattante S Zollino M Marangi G Luigetti M Del Grande A P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis Neuromuscul Disord 2012 22 73 75 10.1016/j.nmd.2011.08.003 21907581
Conte A, Lattante S, Zollino M, Marangi G, Luigetti M, Del Grande A, et al. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul Disord. 2012;22:73–5.21907581 10.1016/j.nmd.2011.08.003
119. Sasaki S Iwata M Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis J Neuropathol Exp Neurol 2007 66 10 16 10.1097/nen.0b013e31802c396b 17204932
Sasaki S, Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2007;66:10–6.17204932 10.1097/nen.0b013e31802c396b
120. De Vos KJ Hafezparast M Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis 2017 105 283 299 10.1016/j.nbd.2017.02.004 28235672
De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis. 2017;105:283–99.28235672 10.1016/j.nbd.2017.02.004
121. Wiedemann FR Manfredi G Mawrin C Beal MF Schon EA Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients J Neurochem 2002 80 616 625 10.1046/j.0022-3042.2001.00731.x 11841569
Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem. 2002;80:616–25.11841569 10.1046/j.0022-3042.2001.00731.x
122. Ghiasi P Hosseinkhani S Noori A Nafissi S Khajeh K Mitochondrial complex I deficiency and ATP/ADP ratio in lymphocytes of amyotrophic lateral sclerosis patients Neurol Res 2012 34 297 303 10.1179/1743132812Y.0000000012 22450425
Ghiasi P, Hosseinkhani S, Noori A, Nafissi S, Khajeh K. Mitochondrial complex I deficiency and ATP/ADP ratio in lymphocytes of amyotrophic lateral sclerosis patients. Neurol Res. 2012;34:297–303.22450425 10.1179/1743132812Y.0000000012
123. Siklós L Engelhardt J Harati Y Smith RG Joó F Appel SH Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis Ann Neurol 1996 39 203 216 10.1002/ana.410390210 8967752
Siklós L, Engelhardt J, Harati Y, Smith RG, Joó F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:203–16.8967752 10.1002/ana.410390210
124. Wiedemann FR Winkler K Kuznetsov AV Bartels C Vielhaber S Feistner H Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis J Neurol Sci 1998 156 65 72 10.1016/S0022-510X(98)00008-2 9559989
Wiedemann FR, Winkler K, Kuznetsov AV, Bartels C, Vielhaber S, Feistner H, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci. 1998;156:65–72.9559989 10.1016/S0022-510X(98)00008-2
125. Crugnola V Lamperti C Lucchini V Ronchi D Peverelli L Prelle A Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis Arch Neurol 2010 67 849 854 10.1001/archneurol.2010.128 20625092
Crugnola V, Lamperti C, Lucchini V, Ronchi D, Peverelli L, Prelle A, et al. Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch Neurol. 2010;67:849–54.20625092 10.1001/archneurol.2010.128
126. Marini C Cistaro A Campi C Calvo A Caponnetto C Nobili FM A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis Eur J Nucl Med Mol Imaging 2016 43 2061 2071 10.1007/s00259-016-3440-3 27421971
Marini C, Cistaro A, Campi C, Calvo A, Caponnetto C, Nobili FM, et al. A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging. 2016;43:2061–71.27421971 10.1007/s00259-016-3440-3
127. Bauckneht M Lai R Miceli A Schenone D Cossu V Donegani MI Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images EJNMMI Res 2020 10 23 10.1186/s13550-020-0607-5 32201914
Bauckneht M, Lai R, Miceli A, Schenone D, Cossu V, Donegani MI, et al. Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Res. 2020;10:23.32201914 10.1186/s13550-020-0607-5
128. Shefner JM Al-Chalabi A Baker MR Cui L de Carvalho M Eisen A A proposal for new diagnostic criteria for ALS Clin Neurophysiol 2020 131 1975 1978 10.1016/j.clinph.2020.04.005 32387049
Shefner JM, Al-Chalabi A, Baker MR, Cui L, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975–8.32387049 10.1016/j.clinph.2020.04.005
129. Wang S Melhem ER Poptani H Woo JH Neuroimaging in amyotrophic lateral sclerosis Neurotherapeutics 2011 8 63 71 10.1007/s13311-010-0011-3 21274686
Wang S, Melhem ER, Poptani H, Woo JH. Neuroimaging in amyotrophic lateral sclerosis. Neurotherapeutics. 2011;8:63–71.21274686 10.1007/s13311-010-0011-3
130. Verber N Shaw PJ Biomarkers in amyotrophic lateral sclerosis: a review of new developments Curr Opin Neurol 2020 33 662 668 10.1097/WCO.0000000000000854 32796280
Verber N, Shaw PJ. Biomarkers in amyotrophic lateral sclerosis: a review of new developments. Curr Opin Neurol. 2020;33:662–8.32796280 10.1097/WCO.0000000000000854
131. Sousa CM Humbert S Huntingtin: Here, there, everywhere! J Huntingt Dis 2013 2 395 403 10.3233/JHD-130082
Sousa CM, Humbert S. Huntingtin: Here, there, everywhere! J Huntingt Dis. 2013;2:395–403.10.3233/JHD-130082
132. O’Regan GC Farag SH Ostroff GR Tabrizi SJ Andre R Wild-type huntingtin regulates human macrophage function Sci Rep 2020 10 17269 10.1038/s41598-020-74042-8 33057179
O’Regan GC, Farag SH, Ostroff GR, Tabrizi SJ, Andre R. Wild-type huntingtin regulates human macrophage function. Sci Rep. 2020;10:17269.33057179 10.1038/s41598-020-74042-8
133. Zuccato C Tartari M Crotti A Goffredo D Valenza M Conti L Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes Nat Genet 2003 35 76 83 10.1038/ng1219 12881722
Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35:76–83.12881722 10.1038/ng1219
134. Ismailoglu I Chen Q Popowski M Yang L Gross SS Brivanlou AH Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells Dev Biol 2014 391 230 240 10.1016/j.ydbio.2014.04.005 24780625
Ismailoglu I, Chen Q, Popowski M, Yang L, Gross SS, Brivanlou AH. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. Dev Biol. 2014;391:230–40.24780625 10.1016/j.ydbio.2014.04.005
135. Gil JM Rego AC Mechanisms of neurodegeneration in Huntington’s disease Eur J Neurosci 2008 27 2803 2820 10.1111/j.1460-9568.2008.06310.x 18588526
Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci. 2008;27:2803–20.18588526 10.1111/j.1460-9568.2008.06310.x
136. Mo C Hannan AJ Renoir T Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington’s disease Neurosci Biobehav Rev 2015 52 178 192 10.1016/j.neubiorev.2015.03.003 25770041
Mo C, Hannan AJ, Renoir T. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington’s disease. Neurosci Biobehav Rev. 2015;52:178–92.25770041 10.1016/j.neubiorev.2015.03.003
137. Wexler NS Lorimer J Porter J Gomez F Moskowitz C Shackell E Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset Proc Natl Acad Sci USA 2004 101 3498 3503 10.1073/pnas.0308679101 14993615
Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA. 2004;101:3498–503.14993615 10.1073/pnas.0308679101
138. Anca MH Gazit E Loewenthal R Ostrovsky O Frydman M Giladi N Different phenotypic expression in monozygotic twins with Huntington disease Am J Med Genet A 2004 124A 89 91 10.1002/ajmg.a.20328 14679593
Anca MH, Gazit E, Loewenthal R, Ostrovsky O, Frydman M, Giladi N. Different phenotypic expression in monozygotic twins with Huntington disease. Am J Med Genet A. 2004;124A:89–91.14679593 10.1002/ajmg.a.20328
139. Friedman JH Trieschmann ME Myers RH Fernandez HH Monozygotic twins discordant for Huntington disease after 7 years Arch Neurol 2005 62 995 997 10.1001/archneur.62.6.995 15956172
Friedman JH, Trieschmann ME, Myers RH, Fernandez HH. Monozygotic twins discordant for Huntington disease after 7 years. Arch Neurol. 2005;62:995–7.15956172 10.1001/archneur.62.6.995
140. Beal MF Brouillet E Jenkins B Henshaw R Rosen B Hyman BT Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate J Neurochem 1993 61 1147 1150 10.1111/j.1471-4159.1993.tb03633.x 7689641
Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem. 1993;61:1147–50.7689641 10.1111/j.1471-4159.1993.tb03633.x
141. Marder K Gu Y Eberly S Tanner CM Scarmeas N Oakes D Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease JAMA Neurol 2013 70 1382 1388 24000094
Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, et al. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013;70:1382–8.24000094
142. Trembath MK Horton ZA Tippett L Collins VR Churchyard A Velakoulis D A retrospective study of the impact of lifestyle on age at onset of Huntington disease Mov Disord 2010 25 1444 1450 10.1002/mds.23108 20629137
Trembath MK, Horton ZA, Tippett L, Collins VR, Churchyard A, Velakoulis D, et al. A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord. 2010;25:1444–50.20629137 10.1002/mds.23108
143. Kim J Moody JP Edgerly CK Bordiuk OL Cormier K Smith K Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease Hum Mol Genet 2010 19 3919 3935 10.1093/hmg/ddq306 20660112
Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet. 2010;19:3919–35.20660112 10.1093/hmg/ddq306
144. Shirendeb U Reddy AP Manczak M Calkins MJ Mao P Tagle DA Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage Hum Mol Genet 2011 20 1438 1455 10.1093/hmg/ddr024 21257639
Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet. 2011;20:1438–55.21257639 10.1093/hmg/ddr024
145. Cui L Jeong H Borovecki F Parkhurst CN Tanese N Krainc D Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration Cell 2006 127 59 69 10.1016/j.cell.2006.09.015 17018277
Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127:59–69.17018277 10.1016/j.cell.2006.09.015
146. Saft C Zange J Andrich J Müller K Lindenberg K Landwehrmeyer B Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease Mov Disord 2005 20 674 679 10.1002/mds.20373 15704211
Saft C, Zange J, Andrich J, Müller K, Lindenberg K, Landwehrmeyer B, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord. 2005;20:674–9.15704211 10.1002/mds.20373
147. Panov AV Gutekunst C Leavitt BR Hayden MR Burke JR Strittmatter WJ Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines Nat Neurosci 2002 5 731 736 10.1038/nn884 12089530
Panov AV, Gutekunst C, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5:731–6.12089530 10.1038/nn884
148. Browne SE Bowling AC MacGarvey U Baik MJ Berger SC Muqit MK Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia Ann Neurol 1997 41 646 653 10.1002/ana.410410514 9153527
Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MK, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41:646–53.9153527 10.1002/ana.410410514
149. Arenas J Campos Y Ribacoba R Martin MA Rubio JC Ablanedo P Complex I defect in muscle from patients with Huntington’s disease Ann Neurol 1998 43 397 400 10.1002/ana.410430321 9506560
Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, et al. Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol. 1998;43:397–400.9506560 10.1002/ana.410430321
150. Tellez-Nagel I Johnson AB Terry RD Studies on brain biopsies of patients with Huntington’s chorea J Neuropathol Exp Neurol 1974 1974 33 308 332 10.1097/00005072-197404000-00008
Tellez-Nagel I, Johnson AB, Terry RD. Studies on brain biopsies of patients with Huntington’s chorea. J Neuropathol Exp Neurol. 1974;1974(33):308–32.10.1097/00005072-197404000-00008
151. Polidori MC Mecocci P Browne SE Senin U Beal MF Oxidative damage to mitochondrial DNA in Huntington’s disease parietal cortex Neurosci Lett 1999 272 53 56 10.1016/S0304-3940(99)00578-9 10507541
Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF. Oxidative damage to mitochondrial DNA in Huntington’s disease parietal cortex. Neurosci Lett. 1999;272:53–6.10507541 10.1016/S0304-3940(99)00578-9
152. Gaura V Lavisse S Payoux P Goldman S Verny C Krystkowiak P Association between motor symptoms and brain metabolism in early Huntington disease JAMA Neurol 2017 74 1088 1096 10.1001/jamaneurol.2017.1200 28672395
Gaura V, Lavisse S, Payoux P, Goldman S, Verny C, Krystkowiak P, et al. Association between motor symptoms and brain metabolism in early Huntington disease. JAMA Neurol. 2017;74:1088–96.28672395 10.1001/jamaneurol.2017.1200
153. McColgan P Tabrizi SJ Huntington’s disease: a clinical review Eur J Neurol 2018 25 24 34 10.1111/ene.13413 28817209
McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25:24–34.28817209 10.1111/ene.13413
154. Weir DW Sturrock A Leavitt BR Development of biomarkers for Huntington’s disease Lancet Neurol 2011 10 573 590 10.1016/S1474-4422(11)70070-9 21601164
Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington’s disease. Lancet Neurol. 2011;10:573–90.21601164 10.1016/S1474-4422(11)70070-9
155. Silajdžić E Björkqvist M A critical evaluation of wet biomarkers for Huntington’s disease: current status and ways forward J Huntingt Dis 2018 7 109 135 10.3233/JHD-170273
Silajdžić E, Björkqvist M. A critical evaluation of wet biomarkers for Huntington’s disease: current status and ways forward. J Huntingt Dis. 2018;7:109–35.10.3233/JHD-170273
156. Southam CM Ehrlich J Effects of extract of western red-cedar heartwood on certain wood-decaying fungi in culture Phytopathol 1943 33 517 524
Southam CM, Ehrlich J. Effects of extract of western red-cedar heartwood on certain wood-decaying fungi in culture. Phytopathol. 1943;33:517–24.
157. Ristow M Schmeisser K Mitohormesis: promoting health and lifespan by increased levels of reactive oxygen species (ROS) Dose Response 2014 12 288 341 10.2203/dose-response.13-035.Ristow 24910588
Ristow M, Schmeisser K. Mitohormesis: promoting health and lifespan by increased levels of reactive oxygen species (ROS). Dose Response. 2014;12:288–341.24910588 10.2203/dose-response.13-035.Ristow
158. Harman D Aging: a theory based on free radical and radiation chemistry J Gerontol 1956 11 298 300 10.1093/geronj/11.3.298 13332224
Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298–300.13332224 10.1093/geronj/11.3.298
159. Harman D The biologic clock: The mitochondria? J Am Geriatr Soc 1972 20 145 147 10.1111/j.1532-5415.1972.tb00787.x 5016631
Harman D. The biologic clock: The mitochondria? J Am Geriatr Soc. 1972;20:145–7.5016631 10.1111/j.1532-5415.1972.tb00787.x
160. Chandel NS Evolution of mitochondria as signaling organelles Cell Metab 2015 22 204 206 10.1016/j.cmet.2015.05.013 26073494
Chandel NS. Evolution of mitochondria as signaling organelles. Cell Metab. 2015;22:204–6.26073494 10.1016/j.cmet.2015.05.013
161. Finkel T Oxygen radicals and signaling Curr Opin Cell Biol 1998 10 248 253 10.1016/S0955-0674(98)80147-6 9561849
Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol. 1998;10:248–53.9561849 10.1016/S0955-0674(98)80147-6
162. Sena LA Chandel NS Physiological roles of mitochondrial reactive oxygen species Mol Cell 2012 48 158 167 10.1016/j.molcel.2012.09.025 23102266
Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48:158–67.23102266 10.1016/j.molcel.2012.09.025
163. Tapia PC Sublethal mitochondrial stress with an attendant stoichiometric augmentation of reactive oxygen species may precipitate many of the beneficial alterations in cellular physiology produced by caloric restriction, intermittent fasting, exercise and dietary phytonutrients: ‘mitohormesis’ for health and vitality Med Hypotheses 2006 66 832 843 10.1016/j.mehy.2005.09.009 16242247
Tapia PC. Sublethal mitochondrial stress with an attendant stoichiometric augmentation of reactive oxygen species may precipitate many of the beneficial alterations in cellular physiology produced by caloric restriction, intermittent fasting, exercise and dietary phytonutrients: ‘mitohormesis’ for health and vitality. Med Hypotheses. 2006;66:832–43.16242247 10.1016/j.mehy.2005.09.009
164. Yun J Finkel T Mitohormesis Cell Metab 2014 19 757 766 10.1016/j.cmet.2014.01.011 24561260
Yun J, Finkel T. Mitohormesis. Cell Metab. 2014;19:757–66.24561260 10.1016/j.cmet.2014.01.011
165. Cheng YW Liu J Finkel T Mitohormesis Cell Metab 2023 35 1872 1886 10.1016/j.cmet.2023.10.011 37939657
Cheng YW, Liu J, Finkel T. Mitohormesis. Cell Metab. 2023;35:1872–86.37939657 10.1016/j.cmet.2023.10.011
166. Lee Y Lee D Mitochondrial toxins and healthy lifestyle meet at the crossroad of hormesis Diabetes Metab J 2019 43 568 577 10.4093/dmj.2019.0143 31694079
Lee Y, Lee D. Mitochondrial toxins and healthy lifestyle meet at the crossroad of hormesis. Diabetes Metab J. 2019;43:568–77.31694079 10.4093/dmj.2019.0143
167. Gomez-Pinilla F The influences of diet and exercise on mental health through hormesis Aging Res Rev 2008 7 49 62 10.1016/j.arr.2007.04.003
Gomez-Pinilla F. The influences of diet and exercise on mental health through hormesis. Aging Res Rev. 2008;7:49–62.10.1016/j.arr.2007.04.003
168. Rattan SIS Hormesis in aging Ageing Res Rev 2008 7 63 78 10.1016/j.arr.2007.03.002 17964227
Rattan SIS. Hormesis in aging. Ageing Res Rev. 2008;7:63–78.17964227 10.1016/j.arr.2007.03.002
169. Kim S Lee Y Choi J Jacobs DR Jr Lee D Evolutionarily adapted hormesis-inducing stressors can be a practical solution to mitigate harmful effects of chronic exposure to low dose chemical mixtures Environ Pollut 2018 233 725 734 10.1016/j.envpol.2017.10.124 29126094
Kim S, Lee Y, Choi J, Jacobs DR Jr, Lee D. Evolutionarily adapted hormesis-inducing stressors can be a practical solution to mitigate harmful effects of chronic exposure to low dose chemical mixtures. Environ Pollut. 2018;233:725–34.29126094 10.1016/j.envpol.2017.10.124
170. Li YP Fekih IB Fru EC Moraleda-Munoz A Li X Rosen BP Antimicrobial activity of metals and metalloids Annu Rev Microbiol 2021 75 175 197 10.1146/annurev-micro-032921-123231 34343021
Li YP, Fekih IB, Fru EC, Moraleda-Munoz A, Li X, Rosen BP, et al. Antimicrobial activity of metals and metalloids. Annu Rev Microbiol. 2021;75:175–97.34343021 10.1146/annurev-micro-032921-123231
171. Rong Z Tu P Xu P Sun Y Yu F Tu N The mitochondrial response to DNA damage Front Cell Dev Biol 2021 9 669379 10.3389/fcell.2021.669379 34055802
Rong Z, Tu P, Xu P, Sun Y, Yu F, Tu N, et al. The mitochondrial response to DNA damage. Front Cell Dev Biol. 2021;9: 669379.34055802 10.3389/fcell.2021.669379
172. Meyer JN Leuthner TC Luz AL Mitochondrial fusion, fission, and mitochondrial toxicity Toxicology 2017 391 42 53 10.1016/j.tox.2017.07.019 28789970
Meyer JN, Leuthner TC, Luz AL. Mitochondrial fusion, fission, and mitochondrial toxicity. Toxicology. 2017;391:42–53.28789970 10.1016/j.tox.2017.07.019
173. Lanphear BP Low-level toxicity of chemicals: No acceptable levels? PLoS Biol 2017 15 e2003066 10.1371/journal.pbio.2003066 29257830
Lanphear BP. Low-level toxicity of chemicals: No acceptable levels? PLoS Biol. 2017;15: e2003066.29257830 10.1371/journal.pbio.2003066
174. Calabrese EJ Mattson MP How does hormesis impact biology, toxicology, and medicine? NPJ Aging Mech Dis 2017 3 13 10.1038/s41514-017-0013-z 28944077
Calabrese EJ, Mattson MP. How does hormesis impact biology, toxicology, and medicine? NPJ Aging Mech Dis. 2017;3:13.28944077 10.1038/s41514-017-0013-z
175. Lee D Jacobs DR Jr Firm human evidence on harms of endocrine-disrupting chemicals was unlikely to be obtainable for methodological reasons J Clin Epidemiol 2019 107 107 115 10.1016/j.jclinepi.2018.12.005 30543909
Lee D, Jacobs DR Jr. Firm human evidence on harms of endocrine-disrupting chemicals was unlikely to be obtainable for methodological reasons. J Clin Epidemiol. 2019;107:107–15.30543909 10.1016/j.jclinepi.2018.12.005
176. Crittenden AN Schnorr SL Current views on hunter–gatherer nutrition and the evolution of the human diet Am J Phys Anthropol 2017 162 Suppl 63 84 109 10.1002/ajpa.23148 28105723
Crittenden AN, Schnorr SL. Current views on hunter–gatherer nutrition and the evolution of the human diet. Am J Phys Anthropol. 2017;162(Suppl 63):84–109.28105723 10.1002/ajpa.23148
177. Aon MA Cortassa S O’Rourke B Redox-optimized ROS balance: a unifying hypothesis Biochim Biophys Acta 2010 1797 865 877 10.1016/j.bbabio.2010.02.016 20175987
Aon MA, Cortassa S, O’Rourke B. Redox-optimized ROS balance: a unifying hypothesis. Biochim Biophys Acta. 2010;1797:865–77.20175987 10.1016/j.bbabio.2010.02.016
178. Yan LJ Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress J Diabetes Res 2014 2014 137919 10.1155/2014/137919 25019091
Yan LJ. Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res. 2014;2014: 137919.25019091 10.1155/2014/137919
179. Ludwig DS Willett WC Volek JS Neuhouser ML Dietary fat: From foe to friend? Science 2018 362 764 770 10.1126/science.aau2096 30442800
Ludwig DS, Willett WC, Volek JS, Neuhouser ML. Dietary fat: From foe to friend? Science. 2018;362:764–70.30442800 10.1126/science.aau2096
180. Cunnane SC Trushina E Morland C Prigione A Casadesus G Andrews ZB Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing Nat Rev Drug Discov 2020 2020 19 609 633 10.1038/s41573-020-0072-x
Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;2020(19):609–33.10.1038/s41573-020-0072-x
181. Cunnane SC Courchesne-Loyer A St-Pierre V Valdenberghe C Pierotti T Fortier M Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease Ann N Y Acad Sci 2016 1367 12 20 10.1111/nyas.12999 26766547
Cunnane SC, Courchesne-Loyer A, St-Pierre V, Valdenberghe C, Pierotti T, Fortier M, et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann N Y Acad Sci. 2016;1367:12–20.26766547 10.1111/nyas.12999
182. de Cabo R Mattson MP Effects of intermittent fasting on health, aging, and disease N Engl J Med 2019 381 2541 2551 10.1056/NEJMra1905136 31881139
de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019;381:2541–51.31881139 10.1056/NEJMra1905136
183. Gano LB Patel M Rho JM Ketogenic diets, mitochondria, and neurological diseases J Lipid Res 2014 55 2211 2228 10.1194/jlr.R048975 24847102
Gano LB, Patel M, Rho JM. Ketogenic diets, mitochondria, and neurological diseases. J Lipid Res. 2014;55:2211–28.24847102 10.1194/jlr.R048975
184. Taylor MK Sullivan DK Mahnken JD Burns JM Swerdlow RH Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer’s disease Alzheimers Dement 2018 4 28 36
Taylor MK, Sullivan DK, Mahnken JD, Burns JM, Swerdlow RH. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer’s disease. Alzheimers Dement. 2018;4:28–36.
185. Brandt J Buchholz A Henry-Barron B Vizthum D Avramopoulos D Cervenka MC Preliminary report on the feasibility and efficacy of the modified Atkins diet for treatment of mild cognitive impairment and early Alzheimer’s disease J Alzheimers Dis 2019 68 969 981 10.3233/JAD-180995 30856112
Brandt J, Buchholz A, Henry-Barron B, Vizthum D, Avramopoulos D, Cervenka MC. Preliminary report on the feasibility and efficacy of the modified Atkins diet for treatment of mild cognitive impairment and early Alzheimer’s disease. J Alzheimers Dis. 2019;68:969–81.30856112 10.3233/JAD-180995
186. Phillips MCL Deprez LM Mortimer GMN Murtagh DKJ McCoy S Mylchreest R Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease Alzheimers Res Ther 2021 13 51 10.1186/s13195-021-00783-x 33622392
Phillips MCL, Deprez LM, Mortimer GMN, Murtagh DKJ, McCoy S, Mylchreest R, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimers Res Ther. 2021;13:51.33622392 10.1186/s13195-021-00783-x
187. Buchholz A Deme P Betz JF Brandt J Haughey N Cervenka MC A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease Front Endocrinol 2024 15 1182519 10.3389/fendo.2024.1182519
Buchholz A, Deme P, Betz JF, Brandt J, Haughey N, Cervenka MC. A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease. Front Endocrinol. 2024;15:1182519.10.3389/fendo.2024.1182519
188. Vanitallie TB Nonas C Di Rocco A Boyar K Hyams K Heymsfield SB Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study Neurology 2005 64 728 730 10.1212/01.WNL.0000152046.11390.45 15728303
Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology. 2005;64:728–30.15728303 10.1212/01.WNL.0000152046.11390.45
189. Phillips MCL Murtagh DKJ Gilbertson LJ Asztely FJS Lynch CDP Low-fat versus ketogenic diet in Parkinson’s disease: a pilot randomized controlled trial Mov Disord 2018 33 1306 1314 10.1002/mds.27390 30098269
Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson’s disease: a pilot randomized controlled trial. Mov Disord. 2018;33:1306–14.30098269 10.1002/mds.27390
190. Krikorian R Shidler MD Summer SS Sullivan PG Duker AP Isaacson RS Espay AJ Nutritional ketosis for mild cognitive impairment in Parkinson’s disease: a controlled pilot trial Clin Park Relat Disord 2019 1 41 47 34316598
Krikorian R, Shidler MD, Summer SS, Sullivan PG, Duker AP, Isaacson RS, Espay AJ. Nutritional ketosis for mild cognitive impairment in Parkinson’s disease: a controlled pilot trial. Clin Park Relat Disord. 2019;1:41–7.34316598
191. Choi AH Delgado M Chen KY Chung ST Courville A Turner SA A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson’s disease BMC Neurol 2024 24 106 10.1186/s12883-024-03603-5 38561682
Choi AH, Delgado M, Chen KY, Chung ST, Courville A, Turner SA, et al. A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson’s disease. BMC Neurol. 2024;24:106.38561682 10.1186/s12883-024-03603-5
192. Phillips MCL Johnston SE Simpson P Chang DK Mather D Dick RJ Time-restricted ketogenic diet in amyotrophic lateral sclerosis: a case study Front Neurol 2024 14 1329541 10.3389/fneur.2023.1329541 38304328
Phillips MCL, Johnston SE, Simpson P, Chang DK, Mather D, Dick RJ. Time-restricted ketogenic diet in amyotrophic lateral sclerosis: a case study. Front Neurol. 2024;14:1329541.38304328 10.3389/fneur.2023.1329541
193. Phillips MCL McManus EJ Brinkhuis M Romero-Ferrando B Time-restricted ketogenic diet in Huntington’s disease: a case study Front Behav Neurosci 2022 16 931636 10.3389/fnbeh.2022.931636 35967897
Phillips MCL, McManus EJ, Brinkhuis M, Romero-Ferrando B. Time-restricted ketogenic diet in Huntington’s disease: a case study. Front Behav Neurosci. 2022;16: 931636.35967897 10.3389/fnbeh.2022.931636
194. Barbaresko J Lellmann AW Schmidt A Lehmann A Amini AM Egert S Dietary factors and neurodegenerative disorders: an umbrella review of meta-analyses of prospective studies Adv Nutr 2020 11 1161 1173 10.1093/advances/nmaa053 32427314
Barbaresko J, Lellmann AW, Schmidt A, Lehmann A, Amini AM, Egert S, et al. Dietary factors and neurodegenerative disorders: an umbrella review of meta-analyses of prospective studies. Adv Nutr. 2020;11:1161–73.32427314 10.1093/advances/nmaa053
195. Petersson SD Philippou E Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence Adv Nutr 2016 7 889 904 10.3945/an.116.012138 27633105
Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. Adv Nutr. 2016;7:889–904.27633105 10.3945/an.116.012138
196. Longo VD Di Tano M Mattson MP Guidi N Intermittent and periodic fasting, longevity and disease Nat Aging 2021 1 47 59 10.1038/s43587-020-00013-3 35310455
Longo VD, Di Tano M, Mattson MP, Guidi N. Intermittent and periodic fasting, longevity and disease. Nat Aging. 2021;1:47–59.35310455 10.1038/s43587-020-00013-3
197. Camandola S Mattson MP Brain metabolism in health, aging, and neurodegeneration EMBO J 2017 36 1474 1492 10.15252/embj.201695810 28438892
Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36:1474–92.28438892 10.15252/embj.201695810
198. Wells RG Neilson LE McHill AW Hiller AL Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms Transl Neurodegener 2024 13 17 10.1186/s40035-024-00406-z 38561866
Wells RG, Neilson LE, McHill AW, Hiller AL. Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms. Transl Neurodegener. 2024;13:17.38561866 10.1186/s40035-024-00406-z
199. Trumpff C Monzel AS Sandi C Menon V Klein H Fujita M Psychosocial experiences are associated with human brain mitochondrial biology bioRxiv 2023 10.1101/2023.10.06.559575 36711938
Trumpff C, Monzel AS, Sandi C, Menon V, Klein H, Fujita M, et al. Psychosocial experiences are associated with human brain mitochondrial biology. bioRxiv. 2023. 10.1101/2023.10.06.559575.36711938 10.1101/2023.10.06.559575
200. Shochat T Impact of lifestyle and technology developments on sleep Nat Sci Sleep 2012 4 19 31 10.2147/NSS.S18891 23616726
Shochat T. Impact of lifestyle and technology developments on sleep. Nat Sci Sleep. 2012;4:19–31.23616726 10.2147/NSS.S18891
201. Crosswell AD Mayer SE Whitehurst LN Picard M Zebarjadian S Epel ES Deep rest: an integrative model of how contemplative practices combat stress and enhance the body’s restorative capacity Psychol Rev 2024 131 247 270 10.1037/rev0000453 38147050
Crosswell AD, Mayer SE, Whitehurst LN, Picard M, Zebarjadian S, Epel ES. Deep rest: an integrative model of how contemplative practices combat stress and enhance the body’s restorative capacity. Psychol Rev. 2024;131:247–70.38147050 10.1037/rev0000453
202. Bierhaus A Wolf J Andrassy M Rohleder N Humpert PM Petrov D A mechanism converting psychosocial stress into mononuclear cell activation Proc Natl Acad Sci USA 2003 100 1920 1925 10.1073/pnas.0438019100 12578963
Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA. 2003;100:1920–5.12578963 10.1073/pnas.0438019100
203. Nithianantharajah J Hannan AJ Enriched environments, experience-dependent plasticity and disorders of the nervous system Nat Rev Neurosci 2006 7 697 709 10.1038/nrn1970 16924259
Nithianantharajah J, Hannan AJ. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci. 2006;7:697–709.16924259 10.1038/nrn1970
204. Sherman DS Mauser J Nuno M Sherzai D The efficacy of cognitive intervention in mild cognitive impairment (MCI): a meta-analysis of outcomes on neuropsychological measures Neuropsychol Rev 2017 27 440 484 10.1007/s11065-017-9363-3 29282641
Sherman DS, Mauser J, Nuno M, Sherzai D. The efficacy of cognitive intervention in mild cognitive impairment (MCI): a meta-analysis of outcomes on neuropsychological measures. Neuropsychol Rev. 2017;27:440–84.29282641 10.1007/s11065-017-9363-3
205. Pozzi FE Appollonio I Ferrarese C Tremolizzo L Can traditional board games prevent or slow down cognitive impairment? A systematic review and meta-analysis J Alzheimers Dis 2023 95 829 845 10.3233/JAD-230473 37638443
Pozzi FE, Appollonio I, Ferrarese C, Tremolizzo L. Can traditional board games prevent or slow down cognitive impairment? A systematic review and meta-analysis. J Alzheimers Dis. 2023;95:829–45.37638443 10.3233/JAD-230473
206. Cruickshank TM Thompson JA Domínguez DJF Reyes AP Bynevelt M Georgiou-Karistianis N The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington’s disease: an exploratory study Brain Behav 2015 5 e00312 10.1002/brb3.312 25642394
Cruickshank TM, Thompson JA, Domínguez DJF, Reyes AP, Bynevelt M, Georgiou-Karistianis N, et al. The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington’s disease: an exploratory study. Brain Behav. 2015;5: e00312.25642394 10.1002/brb3.312
207. Bartlett DM Govus A Rankin T Lampit A Feindel K Poudel G The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington’s disease J Neurol Sci 2020 416 117022 10.1016/j.jns.2020.117022 32688143
Bartlett DM, Govus A, Rankin T, Lampit A, Feindel K, Poudel G, et al. The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington’s disease. J Neurol Sci. 2020;416: 117022.32688143 10.1016/j.jns.2020.117022
208. Sun L Liu T Liu J Gao C Zhang X Physical exercise and mitochondrial function: new therapeutic interventions for psychiatric and neurodegenerative disorders Front Neurol 2022 13 929781 10.3389/fneur.2022.929781 36158946
Sun L, Liu T, Liu J, Gao C, Zhang X. Physical exercise and mitochondrial function: new therapeutic interventions for psychiatric and neurodegenerative disorders. Front Neurol. 2022;13: 929781.36158946 10.3389/fneur.2022.929781
209. Orhan H van Holland B Krab B Moeken J Vermeulen NPE Hollander P Evaluation of a multi-parameter biomarker set for oxidative damage in man: increased urinary excretion of lipid, protein and DNA oxidation products after one hour of exercise Free Radic Res 2004 38 1269 1279 10.1080/10715760400013763 15763951
Orhan H, van Holland B, Krab B, Moeken J, Vermeulen NPE, Hollander P, et al. Evaluation of a multi-parameter biomarker set for oxidative damage in man: increased urinary excretion of lipid, protein and DNA oxidation products after one hour of exercise. Free Radic Res. 2004;38:1269–79.15763951 10.1080/10715760400013763
210. Leek BT Mudaliar SR Henry R Mathieu-Costello O Richardson RS Effect of acute exercise on citrate synthase activity in untrained and trained human skeletal muscle Am J Physiol Regul Integr Comp Physiol 2001 280 R441 R447 10.1152/ajpregu.2001.280.2.R441 11208573
Leek BT, Mudaliar SR, Henry R, Mathieu-Costello O, Richardson RS. Effect of acute exercise on citrate synthase activity in untrained and trained human skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2001;280:R441–7.11208573 10.1152/ajpregu.2001.280.2.R441
211. Ristow M Zarse K How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis) Exp Gerontol 2010 45 410 418 10.1016/j.exger.2010.03.014 20350594
Ristow M, Zarse K. How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp Gerontol. 2010;45:410–8.20350594 10.1016/j.exger.2010.03.014
212. López-Ortiz S Valenzuela PL Seisdedos MM Morales JS Vega T Castillo-García A Exercise interventions in Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials Ageing Res Rev 2021 72 101479 10.1016/j.arr.2021.101479 34601135
López-Ortiz S, Valenzuela PL, Seisdedos MM, Morales JS, Vega T, Castillo-García A, et al. Exercise interventions in Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Ageing Res Rev. 2021;72: 101479.34601135 10.1016/j.arr.2021.101479
213. Gamborg M Hvid LG Dalgas U Langeskov-Christensen M Parkinson’s disease and intensive exercise therapy—an updated systematic review and meta-analysis Acta Neurol Scand 2022 145 504 528 10.1111/ane.13579 34997759
Gamborg M, Hvid LG, Dalgas U, Langeskov-Christensen M. Parkinson’s disease and intensive exercise therapy—an updated systematic review and meta-analysis. Acta Neurol Scand. 2022;145:504–28.34997759 10.1111/ane.13579
214. Meng L Li X Li C Tsang RCC Chen Y Ge Y Effects of exercise in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis Am J Phys Med Rehabil 2020 99 801 810 10.1097/PHM.0000000000001419 32452880
Meng L, Li X, Li C, Tsang RCC, Chen Y, Ge Y, et al. Effects of exercise in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2020;99:801–10.32452880 10.1097/PHM.0000000000001419
215. Mueller SM Petersen JA Jung HH Exercise in Huntington’s disease: current state and clinical significance Tremor Other Hyperkinet Mov 2019 9 601 10.5334/tohm.515
Mueller SM, Petersen JA, Jung HH. Exercise in Huntington’s disease: current state and clinical significance. Tremor Other Hyperkinet Mov. 2019;9:601.10.5334/tohm.515
216. Knechtle B Nikolaidis PT Physiology and pathophysiology in ultra-marathon running Front Physiol 2018 9 634 10.3389/fphys.2018.00634 29910741
Knechtle B, Nikolaidis PT. Physiology and pathophysiology in ultra-marathon running. Front Physiol. 2018;9:634.29910741 10.3389/fphys.2018.00634
217. Picard M Pathways to aging: the mitochondrion at the intersection of biological and psychosocial sciences J Aging Res 2011 2011 814096 10.4061/2011/814096 21961065
Picard M. Pathways to aging: the mitochondrion at the intersection of biological and psychosocial sciences. J Aging Res. 2011;2011: 814096.21961065 10.4061/2011/814096
218. Picard M McEwen BS Psychological stress and mitochondria: a systematic review Psychosom Med 2018 80 141 153 10.1097/PSY.0000000000000545 29389736
Picard M, McEwen BS. Psychological stress and mitochondria: a systematic review. Psychosom Med. 2018;80:141–53.29389736 10.1097/PSY.0000000000000545
219. Evans IEM Martyr A Collins R Brayne C Clare L Social isolation and cognitive function in later life: a systematic review and meta-analysis J Alzheimers Dis 2019 70 S119 S144 10.3233/JAD-180501 30372678
Evans IEM, Martyr A, Collins R, Brayne C, Clare L. Social isolation and cognitive function in later life: a systematic review and meta-analysis. J Alzheimers Dis. 2019;70:S119–44.30372678 10.3233/JAD-180501
220. Kelly ME Duff H Kelly S McHugh Power JE Brennan S Lawlor BA The impact of social activities, social networks, social support and social relationships on the cognitive functioning of healthy older adults: a systematic review Syst Rev 2017 6 259 10.1186/s13643-017-0632-2 29258596
Kelly ME, Duff H, Kelly S, McHugh Power JE, Brennan S, Lawlor BA, et al. The impact of social activities, social networks, social support and social relationships on the cognitive functioning of healthy older adults: a systematic review. Syst Rev. 2017;6:259.29258596 10.1186/s13643-017-0632-2
221. Leung P Orrell M Orgeta V Social support group interventions in people with dementia and mild cognitive impairment: a systematic review of the literature Int J Geriatr Psychiatry 2015 30 1 9 10.1002/gps.4166 24990344
Leung P, Orrell M, Orgeta V. Social support group interventions in people with dementia and mild cognitive impairment: a systematic review of the literature. Int J Geriatr Psychiatry. 2015;30:1–9.24990344 10.1002/gps.4166
222. Richardson RB Mailloux RJ Mitochondria need their sleep: redox, bioenergetics, and temperature regulation of circadian rhythms and the role of cysteine-mediated redox signaling, uncoupling proteins, and substrate cycles Antioxidants (Basel) 2023 12 674 10.3390/antiox12030674 36978924
Richardson RB, Mailloux RJ. Mitochondria need their sleep: redox, bioenergetics, and temperature regulation of circadian rhythms and the role of cysteine-mediated redox signaling, uncoupling proteins, and substrate cycles. Antioxidants (Basel). 2023;12:674.36978924 10.3390/antiox12030674
223. Andreazza AC Andersen ML Alvarenga TA De-Oliviera MR Armani F Ruiz FS Impairment of the mitochondrial electron transport chain due to sleep deprivation in mice J Psychiatr Res 2010 44 775 780 10.1016/j.jpsychires.2010.01.015 20176368
Andreazza AC, Andersen ML, Alvarenga TA, De-Oliviera MR, Armani F, Ruiz FS, et al. Impairment of the mitochondrial electron transport chain due to sleep deprivation in mice. J Psychiatr Res. 2010;44:775–80.20176368 10.1016/j.jpsychires.2010.01.015
224. Xie L Kang H Xu Q Chen MJ Liao Y Thiyagarajan M Sleep drives metabolite clearance from the adult brain Science 2013 342 373 377 10.1126/science.1241224 24136970
Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373–7.24136970 10.1126/science.1241224
225. Mauri S Favaro M Bernardo G Mazzotta GM Ziviani E Mitochondrial autophagy in the sleeping brain Front Cell Dev Biol 2022 10 956394 10.3389/fcell.2022.956394 36092697
Mauri S, Favaro M, Bernardo G, Mazzotta GM, Ziviani E. Mitochondrial autophagy in the sleeping brain. Front Cell Dev Biol. 2022;10: 956394.36092697 10.3389/fcell.2022.956394
226. Scott AJ Webb TL Martyn-St James M Rowse G Weich S Improving sleep quality leads to better mental health: a meta-analysis of randomised controlled trials Sleep Med Rev 2021 60 101556 10.1016/j.smrv.2021.101556 34607184
Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality leads to better mental health: a meta-analysis of randomised controlled trials. Sleep Med Rev. 2021;60: 101556.34607184 10.1016/j.smrv.2021.101556
227. Fincham GW Strauss C Montero-Marin J Cavanagh K Effect of breathwork on stress and mental health: a meta-analysis of randomised-controlled trials Sci Rep 2023 13 432 10.1038/s41598-022-27247-y 36624160
Fincham GW, Strauss C, Montero-Marin J, Cavanagh K. Effect of breathwork on stress and mental health: a meta-analysis of randomised-controlled trials. Sci Rep. 2023;13:432.36624160 10.1038/s41598-022-27247-y
228. Russell-Williams J Jaroudi W Perich T Hoscheidt S El Haj M Moustafa AA Mindfulness and meditation: treating cognitive impairment and reducing stress in dementia Rev Neurosci 2018 29 791 804 10.1515/revneuro-2017-0066 29466242
Russell-Williams J, Jaroudi W, Perich T, Hoscheidt S, El Haj M, Moustafa AA. Mindfulness and meditation: treating cognitive impairment and reducing stress in dementia. Rev Neurosci. 2018;29:791–804.29466242 10.1515/revneuro-2017-0066
229. van der Heide A Meinders MJ Speckens AEM Peerbolte TF Bloem BR Helmich RC Stress and mindfulness in Parkinson’s disease: clinical effects and potential underlying mechanisms Mov Disord 2021 36 64 70 10.1002/mds.28345 33094858
van der Heide A, Meinders MJ, Speckens AEM, Peerbolte TF, Bloem BR, Helmich RC. Stress and mindfulness in Parkinson’s disease: clinical effects and potential underlying mechanisms. Mov Disord. 2021;36:64–70.33094858 10.1002/mds.28345
